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Development of an Ecological Model to Predict Risk for Acquisition of Clostridium
difficile-Associated Diarrhea During Acute Care Hospitalization
Susan Elaine Steele
ABSTRACT
Background: The traditional model of infection control has failed to stop the spread of
emerging infectious diseases such as Clostridium difficile-associated diarrhea (CDAD) in
the acute care environment. Ecological models, which rely upon identification of
susceptible hosts, offer an alternative to the prevention of deadly outbreaks. Previous
epidemiological research has identified a number of risk factors associated with CDAD.
Utilization of this body of research by nurses is limited due to methodological issues that
introduce bias and confounding, and use of variables that have limited meaning to the
practicing clinical nurse.
Aim: The aim of this study was to develop an ecological model useful for nurses in
predicting the susceptibility of individuals to CDAD during an acute care hospital stay.
Method: A case-control study compared 66 cases with CDAD to 66 controls matched for
the temporal and spatial risk factors of hospital admission date and geographic nursing
care unit within the institution. The two subject groups were compared on variables of
age, antibiotic burden, laxative or bowel preparation exposure, nutritional status, gastric
acid suppression therapy, enteral feeding exposure, and severity of illness as measured on
the Horn Severity of Illness index. All subjects were hospitalized between January 1,
2000 and December 31, 2006.
vi

Results: On univariate analysis, age, severity of illness, serum albumin levels, length of
exposure, and proton pump inhibitor drug burden were significantly associated with
CDAD status. Following multivariate analysis, only severity of illness, length of
exposure, and decreased antibiotic drug burden were significantly associated with the
development of hospital-acquired CDAD.
Conclusions: This study supports the use of an ecological perspective in identifying risk
factors and interventions to prevent the future spread of this infectious disease.

vii

Chapter One
Introduction
Clostridium difficile (C. difficile) is a gram-positive, spore-forming anaerobe, first
identified in 1935 in the normal enteric flora of infants (Hall & O'Toole, 1935). A caseseries analysis published in the early 1960’s discounted a serious health threat from C.
difficile, concluding that either the toxin was not produced within the human body or that
humans did not exhibit a marked sensitivity to the toxins produced by the bacteria (Smith
& King, 1962). However, discovery of a link between antibiotic-associated
pseudomembranous colitis and a toxin-producing strain of a Clostridium species in the
1970’s clearly established the organism as a human pathogen and triggered a series of
investigations associating various antibiotics with the development of the disease
(Bartlett, 2004).
By 1980, C. difficile- associated diarrhea (CDAD) was identified as a serious
nosocomial infection (Mulligan, George, Rolfe, & Finegold, 1980; Peikin, Galdibini, &
Bartlett, 1980). Since the 1980’s, research has expanded understanding that C. difficile
infection occurs in a continuum extending from asymptomatic carriage to fulminating
pseudomembranous colitis. Toxigenic strains of C. difficile have been isolated from
feces of healthy adults not recently exposed to antibiotics, with reported prevalence
ranging from 4.2% to 53.3% (Iizuka et al., 2004; Kato et al., 2001; Nakamura et al.,
1981), indicating that transmission and carriage of the organism may occur undetected
1

among the general population, as well as among institutionalized individuals. Although
such colonization is believed to be transient in most cases, there is evidence that
persistent C. difficile colonization does occur in some individuals (Ozaki et al., 2003).
Among hospital patients, colonization followed by an IgG antibody response has been
associated with a decreased risk of CDAD acquisition after adjustment for age, sex and
disease severity (Kyne, Warny, Qamar & Kelly, 2000), and an acquired immune response
to toxin A following an episode of CDAD is believed to be protective against recurrence
of diarrhea (Kyne, Warny, Qamar & Kelly, 2001).
There is indication that increasing numbers of persons are experiencing the most
severe outcomes of C. difficile infection including pseudomembranous colitis and death
(Dallal et al., 2002; Frost, Craun, & Calderon, 1998; Morris et al., 2002; Pepin et al.,
2004),. Most recently, a change in the epidemiologic pattern of the disease has been
noted, including geographically dispersed outbreaks (Krausz et al., 2005; Loo et al.,
2005; McDonald et al., 2005; Warny et al., 2005), an increasingly virulent strain of the
organism (Morris et al., 2002; Pepin et al., 2004; Pepin, Valiquette, & Cossette, 2005),
and susceptibility of populations previously believed to be low risk for acquisition of
CDAD (Centers et al., 2005). Because persons who develop nosocomial CDAD
experience a more than 50% increase in hospital costs, increased length of stay and a
significantly higher mortality rate, the burden of this disease threatens the health care
system (Kyne, Hamel, Polavaram, & Kelly, 2002; Miller, Hyland, Ofner-Agostini,
Gourdeau, & Ishak, 2002).
Investigations in prevention of CDAD have included antibiotic restriction
policies, vaccine development (Kotloff et al., 2001; Sougioultzis et al., 2005), and dietary
2

modulation of intestinal microflora. Dietary interventions have included use of
prebiotics, non-digestible fiber agents that ferment and foster growth of normal flora,
probiotics, live organisms found in healthy flora, and synbiotics, a combination of a
prebiotic and probiotic agent (Bengmark, 2003; Collins & Gibson, 1999). These research
efforts, while somewhat promising, currently lack sufficient evidence to support their use,
and prevention of CDAD is dependent upon traditional infection control processes such
as hand hygiene, isolation, and environmental decontamination.
Epidemiological and biomedical models for the prevention of infectious diseases
are based upon identification, and destruction or elimination of the causative organism.
Such an approach ignores the evolutionary potential of an enormously diverse
prokaryotic domain (Galvani, 2003; Purssell, 2005a, , 2005b) as well as the
environmental and social factors in the modern age that have altered the relationship
between man and microbe (de Albuquerque Possas, 2001; McMichael, 2004; Waldvogel,
2004). In contrast, an ecological model of infectious disease offers an understanding of
the way temporal and spatial relationships between host and pathogen can be altered to
reduce the risk of disease (Koren & Crawford-Brown, 2004).
The human intestine can be described as a complex ecosystem, comprised of a
constantly resurfacing organ playing host to both resident and transient microbes existing
in a state of mutualism (Xu & Gordon, 2003). In healthy adults, the indigenous bacteria
within the intestine control pathogenic invasion via colonization resistance (van der
Waaij, 1989). In return, the host provides mucus, shed epithelial cells, and ingested food
particles which allow the bacteria to thrive in a physiologic bioreactor (Backhed, Ley,
Sonnenburg, Peterson, & Gordon, 2005).
3

CDAD represents a disruption of the intestinal ecosystem, manifested by an
increase in enterococci (Hopkins & MacFarlane, 2002; Ozaki et al., 2003) a decline in
Bifidobacteria and Bacteroides colonization (Hopkins & MacFarlane, 2002), and
proliferation of C. difficile. A number of case series reported successful treatment of
recurrent CDAD by rectal or nasogastric administration of donor stool, further
supporting the importance of a healthy intestinal ecosystem in combating the disease
(Aas, Gessert, & Bakken, 2003; Bowden, Mansberger, & Lykins, 1981; Eiseman, Silen,
Bascom, & Kauvar, 1958; Persky & Brandt, 2000; Schwan, Sjolin, Trottestam, &
Aronsson, 1984; Tvede & Rask-Madsen, 1989). Restoration of the normal colonic flora
has been the focus of increasing research regarding a number of diseases including C.
difficile, driven by advances in genomics and global awareness of emerging infectious
diseases (McMichael, 2004; Rastall et al., 2005). However, there remains a lack of
clinical trial data to help target populations most likely to benefit and to substantiate the
specific agents appropriate for prevention and treatment of CDAD.
Alteration in intestinal ecology can effect diarrhea through disturbances in
motility, defects in the immune system, and failure of colonization resistance (Hawrelak
& Myers, 2004). The development and maintenance of the normal intestinal ecosystem
is influenced by several factors, including age, dietary intake, and systemic drug therapy.
Indigenous bacteria begin to form colonies at the time of birth as a result of
exposure to maternal bacteria in the vagina, and within the first few days of life, the
diversity of the fecal flora changes rapidly (Park et al., 2005).

Early in life, C. difficile

colonization is common, and C. difficile has been demonstrated within the intestinal
microbiota of healthy infants in hospital, home, and day care environments (Larson,
4

Barclay, Honour, & Hill, 1982; Matsuki et al., 2005; Park et al., 2005; Penders et al.,
2005; Stark, Lee, & Parsonage, 1982). As an individual matures, changes in bacterial
composition result in greater species diversity accompanied by a decline in C. difficile
(Hopkins & MacFarlane, 2002; Hopkins, Sharp, & Macfarlane, 2001). However, as an
individual approaches advanced age, a decline in Bifidobacteria and an increase in
enterococci occurs (Hebuterne, 2003; Hopkins & MacFarlane, 2002; Hopkins, Sharp, &
Macfarlane, 2001).
Dietary intake plays a significant role in fecal bacterial colonization. Ingestion of
non-digestible carbohydrates provides nutrition to support the production of various
bacterial species. Both naturally occurring and experimental-supplement induced dietary
intake of oligosaccharides results in an increase in fecal Bifidobacteria levels (Boehm et
al., 2004; Gibson, Beatty, Wang, & Cummings, 1995; Langlands, Hopkins, Coleman, &
Cummings, 2004; Penders et al., 2005; Stark, Lee, & Parsonage, 1982) and the increase is
dose-dependent (Bouhnik et al., 1999). Oligosaccharide supplementation resulted in a
decrease in C. difficile colonization both in vitro (Hopkins & MacFarlane, 2003) and in
healthy adults receiving the supplement during a course of an oral cephalosporin
antibiotic (Orrhage, Svante, & Nord, 2000).
Hospitalization for illness or injury often requires nutritional support via enteral
nutrition (tube feeding). A common gastrointestinal complication of enteral feeding is
diarrhea, with reported incidence ranging from 2.3% to 38% among general hospital
populations and as high as 68% among critically ill adults (Cataldi-Betcher, Seltzer,
Slocum, & Jones, 1983; Elpern, Stutz, Peterson, Gurka, & Skipper, 2004; Heimburger,
Sockwell, & Geels, 1994; Homann, Kemen, Fuessenich, Senkal, & Zumtobel, 1994;
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Montejo, 1999; Pancorbo-Hidalgo, Garcia-Fernandez, & Ramirez-Perez, 2001; C. Smith
et al., 1990). Suggested causes for tube-feeding-associated diarrhea include
hypoalbuminemia, formula intolerance, concomitant use of sorbitol-containing elixir
medications (Eisenberg, 2002) and colonic response to a non-physiologic form of feeding
(Bowling & Silk, 1998). However, enteral nutrition also results in a decrease in
anaerobic and an increase in aerobic bacteria in feces (Schneider et al., 2000; Whelan,
Judd, Preedy, & Taylor, 2004), a trend that may be altered by formulas supplemented
with fiber (Nakao et al., 2002). Enteral feeding and the presence of nasogastric or
percutaneously inserted enteral feeding tubes have been found to have significant
association with the acquisition of CDAD (D. Z. Bliss et al., 1998; Komatsu et al., 2003;
Kyne et al., 1999; Lai, Melvin, Menard, Kotilainen, & Baker, 1997).
Illness and medical treatment also is associated with alteration in the gut
ecosystem. Although antibiotics have received the most attention in investigations, both
acid suppressive and laxative medications also have been implicated in altering colonic
flora. The effect of antibiotics upon intestinal microflora varies both between and within
drug categories. A structured research review of papers published between 1991 and
2000 identified a decrease in obligate anaerobes such as Bacteroides, Bifidobacterium,
and Lactobacillus, an increase in facultative anaerobes such as Enterococcus, and
Streptococcus, and an increase in aerobic organisms such as Pseudomonas (Sullivan,
Edlund, & Nord, 2001) as common antibiotic effects. This same review identified a large
number of cephalosporin agents associated with overgrowth of C. difficile. More recent
publications report similar findings of floral suppression and proliferation of competing
bacteria (Bartosch, Fite, Macfarlane, & McMurdo, 2004; Buhling, Radun, Muller, &
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Malfertheiner, 2001; Hawrelak & Myers, 2004; Madden et al., 2005; Monreal, Pereira, &
Lopes, 2005; Takesue et al., 2002). The ecosystem changes which occur as a result of
antibiotic usage are not immediately reversible with cessation of antibiotic therapy, and it
may take more than a month to return to pretreatment levels of dominant microbial
species (Buhling, Radun, Muller, & Malfertheiner, 2001; De La Cochetiere et al., 2005).
The use of gastric acid suppressive medications has been associated with the
development of CDAD in residents of long-term care facilities, as well as hospitalized
and community-based individuals (Al-Tureihi, Hassoun, Wolf-Klein, & Isenberg, 2005;
Cunningham, Dale, Undy, & Gaunt, 2003; Dial, Alrasadi, Manoukian, Huang, &
Menzies, 2004; Dial, Delaney, Barkun, & Suissa, 2005; L.V. McFarland, Surawicz, &
Stamm, 1990). The exact effect of acid suppressive agents upon intestinal microflora is
not known. It is hypothesized that suppression of gastric acid allows an increased
number of potential pathogens to survive transition from stomach to intestine (Donskey,
2004).
Laxative drugs also may alter intestinal flora. Chronic constipation in adults is
associated with alterations in colonic ecology as compared to healthy controls.
Treatment with both bisacodyl and lactulose result in normalization of the flora (Bouhnik
et al., 2004; Khalif, Quigley, Konovitch, & Maximova, 2005; Zoppi et al., 1998), but
polyethylene glycol-4000 does not exert the same ecological effect (Bouhnik et al.,
2004). Lactulose in particular has been found to promote the growth of lactic acid
bacteria and Bifidobacteria (Salminen & Salminen, 1997), and to suppress the
proliferation of potential pathogens such as Clostridium difficile (Ballongue, Schumann,
& Quignon, 1997; Ito et al., 1997). Laxative usage is a potential confounder in research
7

regarding CDAD, since both the disease and the drug may alter stool consistency and
frequency.
Problem Statement
Through previous research, a number of ecological risk factors pertinent to
hospitalized adults have been identified for the development of CDAD. These risk
factors include advanced age, use of tube feeding, malnutrition, severity of illness, and
the use of medications that alter the intestinal flora, including gastric acid suppressant
agents, antibiotics, and cathartics.
The purpose of this study was to develop and test an ecological model useful to
nurses in predicting risk for the development of Clostridium difficile-associated diarrhea.
It was anticipated that the model would serve three purposes: (1) serve as a foundation
for development of a valid and reliable risk assessment tool (2) aid in the design of future
clinical trials of nurse-directed prevention strategies and (3) assist clinicians in modifying
infection control practices in institutional settings when caring for high-risk individuals.
Hypotheses
This study is designed to test a hypothesis about the risk factors for development
of hospital-acquired CDAD:
H1: Severity of illness, length of exposure, and malnutrition, are significant
predictors for the development of CDAD among cases as compared to C. difficilenegative controls with diarrhea when matched for admission date, and geographic
unit of hospital, and after controlling for the effects of age, tube feeding, cathartic
administration, antibiotic therapy, and acid suppression therapy.

8

Definition of Terms
Diarrhea.
For purposes of this study, diarrhea was defined as at least three stools within a 24
hour period documented within the medical record as “liquid”, “loose”, “unformed”, or
“diarrhea”, or 250 milliliters of liquid stool collected via a colostomy, adhesive fecal
incontinence collection pouch, or a rectally inserted bowel management tube, or at least
1500 milliliters of liquid stool from an ileostomy pouch.
Clostridium difficile-associated diarrhea.
Diarrhea occurring concurrently with or within 7 days of a positive cytotoxin
assay, stool culture, or endoscopic examination consistent with pseudomembranous
colitis.
Antibiotic burden.
Antibiotic burden was defined as the sum of the average daily maintenance doses
of oral or intravenously administered antibiotics received by the patient during the risk
period. These average daily doses were determined by use of the World Health
Organization Defined Daily Dose system (WHO Collaborating Centre for Drug
Statitistics Methodology, 2007)
Length of exposure/risk period.
The length of exposure, or risk period, for this study commenced on the date of
admission to the acute care hospital and ended on the date that a stool specimen was
submitted for Clostridium difficile testing.

9

Significance to Nursing
Nurses spend the most time in the physical proximity of infected and potentially
vulnerable patients within the health care system. Because nursing role functions include
assistance with toileting, they are often able to predict a positive Clostridium difficile
cytotoxin test result based upon knowledge of a patient’s prior antibiotic use and the
presence of a distinctive fecal odor (Johansen, Vasishta, Edison, & Hosein, 2002).
Nurses have been implicated as possible agents in the spread of the disease in hospitals
(Chang & Nelson, 2000; Perry, Marshall, & Jones, 2001), and are responsible in
institutional settings for supervising the environmental decontamination of individual
patient rooms and geographic units, critical to the prevention of disease transmission
(Chang & Nelson, 2000; Kroker, Bower, & Azadian, 2001; Mayfield, Leet, Miller, &
Mundy, 2000; Verity, Wilcox, Fawley, & Parnell, 2001; Wilcox et al., 2003).
Diarrhea is a frequent cause of fecal incontinence in acutely-ill hospitalized adults
(Bliss, Johnson, Savik, Clabots, & Gerding, 2000), requiring increased nursing care hours
and supplies for skin cleansing, treatment of skin breakdown, and linen changes. CDAD
is now recognized as the most common type of infectious nosocomial diarrhea
(McFarland, 1995). Outbreaks of CDAD have been well-documented (Blot et al., 2003;
Johnson et al., 1999; Kuijper et al., 2001) and reported incidence rates of nosocomial
CDAD range from 0.19 to 6.8 per 100 hospital admissions (Dial, Alrasadi, Manoukian,
Huang, & Menzies, 2004; Thomas, Stevenson, Williamson, & Riley, 2002). A global
shortage of qualified professional nurses compromises containment of emerging
infectious diseases in health care settings (Stone, Clarke, Cimiotti, & Correa-de-Araujo,
2004).
10

Traditional methods of preventing the spread of infectious diseases within
hospitals have not proven sufficient to combat emerging infections such as CDAD. An
alternative ecological approach to disease prevention requires change in nursing practice
to decrease the impact of the organism upon human hosts. By strengthening the natural
flora of the hospitalized individual and increasing the spatial and temporal distance
between susceptible persons and potentially infectious organisms, the degree of harm
caused by the organism can be reduced (Purssell, 2005a). Table 1 compares and
contrasts the biomedical and ecological approaches to infectious disease prevention.
Table 1
Prevention and Treatment of Infectious Diseases: Traditional Versus Ecological Models
Model
Aspect of Care

Traditional

Ecological

Detection

Identification of persons with
disease

Identification of persons
susceptible to disease

Symptom treatment

Treat symptoms

Treat only symptoms that have
no benefit for the host

Chemoprophylaxis

Prophylactic administration of
antimicrobial agents

Administration of
biotherapeutic agents to
maintain or restore host flora

Isolation

Isolate persons with disease

Isolate persons with symptoms
and susceptible persons based
on level of susceptibility and
degree of immunosuppression

Environmental
Controls

Uniform environmental
cleaning protocols to remove
pathogens

In addition to environmental
cleaning protocols, increase
spatial and temporal intervals
between susceptible host and
pathogen contact

Note. Adapted from Pursell, 2005a and Pursell, 2005b.
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Key differences in the two approaches lie in the detection of susceptibility to
disease and the modulation of host flora to combat the growth of potentially pathogenic
microbial species. To utilize such an approach, nurses require a simple and reliable risk
assessment tool for estimating susceptibility to CDAD. The development of a predictive
model would enable further development of such a tool.
Summary
CDAD is a serious infection that can be understood as a disturbance of the
intestinal ecology. Identification of the factors that make an individual most susceptible
to CDAD would enable the design of infection control interventions based on ecological
principles to decrease the extent of harm caused by this microorganism. Advancing age,
severity of illness, diet, and use of antibiotic, acid suppressive and cathartic medications
have been identified as factors that disrupt the normal intestinal ecology and may
promote the development of CDAD.
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Chapter Two
Review of the Literature
By virtue of its increasing incidence, virulence and global geographic range,
CDAD is considered an emerging infectious disease. Changes within the environment
and in human ecology are precipitating factors which account for the emergence of most
such diseases (de Albuquerque Possas, 2001; Lederberg, Shope, & Oaks, 1992;
McMichael, 2004; Morse, 1995). Changes in human demographics and behavior
increase both exposure to infectious agents and susceptibility to their deleterious effects.
This chapter will present a review of the analytic epidemiology research literature
identifying human demographic and behavioral risk factors for the development of C.
difficile-associated diarrhea. An ecological model to guide the study of CDAD will be
developed.
A literature search was conducted in both Medline and CINAHL electronic
databases for the years 1995 through March 2006. The keywords “Clostridium difficile”
was paired using the Boolean connector “AND” with each of the following keywords:
“risk factors”, “age”, “antibiotic”, “tube feeding”, “laxative OR bowel preparation”,
“severity of illness” and “acid suppression”. Articles were limited to those published in
the English language, and studies concerning adult subjects in a hospital or institutional
setting, designed to understand risk factors for an initial episode of Clostridium difficileassociated diarrhea. The electronic search was supplemented with ancestral retrievals for
a final yield of 73 publications.
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The sample included one meta-analysis and one structured literature review. The
remaining 71 original research reports included 36 case-control studies, 13 prospective
and nine retrospective cohort studies, three clinical trials, and ten descriptive studies. The
majority of the studies in the review were conducted in North America and Europe;
however, the sample did include studies conducted in Asia and Oceania-Australasia,
indicating potential for some genetic diversity among the study populations. Subjects
were being treated both medically and surgically for a variety of conditions including
cancer, pneumonia, complications of human immunodeficiency virus infection, and
cardiac disease.
Qualitative Assessment
To systematically assess the quality of the clinical trial, case-control and cohort
study publications, a criterion-based checklist was adapted (Downs & Black, 1998). The
original checklist was modified based upon important domains and elements for
systematic review advocated by the Agency for Healthcare Research and Quality (West
et al., 2002).
The checklist items were entered into an Excel spreadsheet and each publication
was subjected to the same questions regarding quality of the published report, internal
validity and external validity of the research methods described, and disclosure of
funding source. Publications were assigned a code of one if the element was present
within the publication and a code of zero if the element was absent. Thus, the both the
number and the percentage of publications that met each of the specified criteria could be
calculated. The ten descriptive studies were not subjected to this checklist assessment, as
the conduct of the studies and the method of reporting were incompatible with this tool.
14

These publications, along with the two systematic reviews, were used to help further
shape understanding of the ecological concepts. Table 2 summarizes the results of this
qualitative review of the publications.
Table 2
Number and Percent of Studies Meeting Evaluation Criteria
Checklist Item
Reporting Quality
Was a hypothesis, aim, or study objective stated?
Were the main findings of the study clearly described?
External Validity
Were inclusion and exclusion criteria used to determine
eligibility for participation in the study?
Were only inclusion criteria, and not exclusion criteria,
identified in the paper?
Were the subjects representative of the entire population from
which they were recruited?
Internal Validity (bias and confounding)
Was an attempt made to blind subjects to the intervention they
have received (clinical trials, n=3)?
Was an attempt made to blind those measuring the main
outcomes of the intervention (clinical trials, n=3)?
Were the statistical tests used to assess the main outcomes
appropriate to the research question?
Were the measurements used to assess the main outcome
accurate (valid and reliable)?
Were subjects in different intervention groups (trials and cohort
studies) or were cases and controls (case-control studies)
recruited from the same population?
Were study subjects randomized to intervention groups
(clinical trials?)
Was there adequate adjustment for confounding in the
statistical analysis from which the main findings were drawn?
Disclosure
Was the funding source for the study identified?

Number

%

52
55

85.25
90.16

20

32.79

20

32.79

40

65.57

1

33.33

1

33.33

55

90.16

52

85.25

32

52.46

1

33.33

35

57.38

13

21.31

Report quality
Within this body of literature, reporting quality was high for two of the criteria
considered. The majority of the published reports included an explicit or implied
15

hypothesis, aim or objective for the study (85%), and clearly described the main findings
of the study (90%). All three interventional studies clearly described the intervention.
However, only 16 (26%) of the observational studies clearly reported a method of
measurement for the exposures or risk factors of interest.
Internal validity
Assessment of internal validity included factors such as blinding and
randomization for the interventional studies, statistical analysis methods, and presence or
absence of bias.
Of the three interventional studies, only one blinded both subjects and those
measuring outcomes to the group assignment (Cleary et al., 1998). The other
interventional studies used no blinding in the study design (Rao, Rao, & Starke, 2003;
Settle, Wilcox, Fawley, Corrado, & Hawkey, 1998). Cleary et al. also was the only study
to include randomization in the assignment of subjects to intervention groups.
Statistical analysis methods used to assess study data were appropriate to the
research question and design in most studies (86%). Although a number of the
observational studies considered more than one risk factor for the development of
CDAD, only 35 studies (57%) described adequate adjustment for the effects of
confounding in discussing the main findings of the studies. Twenty-five studies (41%)
used multivariate statistical techniques in an effort to control the effects of confounding
during data analysis. The most frequently reported type of multivariate data analysis
strategy was stepwise logistic regression. Results of stepwise procedures in multivariate
analysis are easily misinterpreted because predictors may be excluded which are, in fact,
highly correlated with the outcome of interest (Tabachnick & Fidell, 2001). To minimize
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this problem, more liberal criterion for inclusion of predictors following univariate
analysis (p < .15 or .20) is advised. Only four of the multivariate studies in this review
specifically identified variable selection criteria with a univariate significance level
greater than p < .05 (Komatsu et al., 2003; Kyne, Sougioultzis, McFarland, & Kelly,
2002; Muto et al., 2005; Pulvirenti et al., 2002). The remainder of the studies eliminated
variables that might have had an independent association with the development of CDAD
following multivariate testing, and indeed limited inclusion of variables that may have
clinical relevance. Stepwise procedures hold the allure of statistical criteria for decisions
about inclusion of predictors, rather than the tedium of formulating specific hypotheses
about the role of multiple variables in association with CDAD. However, such a strategy
limits the applicability of the predictive model to clinical practice.
A limitation common to most of the studies within this review is the lack of a
consistent case definition for CDAD among studies. Clinically, both the presentation of
diarrhea and confirmatory laboratory stool testing or endoscopic examination are
considered essential for a diagnosis of CDAD. Although 73% of the studies include
some type of change in bowel function as a part of the case definition, the definition of
diarrhea varied greatly between studies. This problem of defining diarrhea and its impact
on the interpretation of diarrhea study findings has been previously discussed (Bliss,
Guenter, & Settel, 1992; Steele, 2006). Diarrhea defined by the number of bowel
movements, consistency of stool, and duration of the symptom varies among studies,
making meta-analysis unrealistic. Reliable instruments exist for classification of stool
characteristics (Bliss, Larson, Burr, & Savik, 2001; Whelan, Judd, & Taylor, 2004).
However, their use in retrospective designs that rely upon medical record documentation
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is impractical. More than half of the studies in this sample were of a retrospective cohort
or case-control design. Confirmatory testing was part of the case definition for 83% of
the original studies. However, a variety of testing methods were used, making metaanalysis, as advocated by Bignardi, questionable. Two studies assigned subjects to case
status based only on the diagnosis recorded in the medical record by a clinician (Buchner
& Sonnenberg, 2001; Harbarth, Samore, & Carmeli, 2001) and a third publication, a
letter to the editor reporting research findings, did not include details regarding case
definition (Iizuka et al., 2004).
A large portion of the studies relied upon laboratory records of diagnostic stool
testing for the selection of subjects and cases. This strategy assumes that all specimens
submitted for C. difficile testing are from symptomatic individuals, and that all persons
without stool testing are both asymptomatic and would produce negative stool testing
results. Thus, a type of diagnostic bias was inherent in the design of these studies.
Comparison of studies is also complicated by the variety of ways in which
specific risk factor exposure was measured. This is especially evident in assessing
antibiotic exposure and severity of illness. Antibiotic exposure was measured by number
of drugs, number of doses, number of days on a specific agent, appropriate versus
inappropriate use, specific drug regimen, and by a simple binary measure of exposure.
Only one study (Al-Eidan, :McElnay, Scott, & Kearney, 2000) attempted to use a
standardized measure of antibiotic exposure, the Defined Daily Doses established by the
World Health Organization for drug utilization research.
Similarly, the concept of severity of illness responsible for hospitalization was
measured in a number of ways. The number of medical or surgical procedures, number
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of organ systems affected, critical care or ventilator use, prolonged hospital stay and
disease staging were all forms of severity assessment. Only two instruments were used
for categorization of this variable in a consistent manner. The Horn’s Severity of Illness
index was used in three studies (Kyne, Sougioultzis, McFarland, & Kelly, 2002;
L.McFarland, 1995; Vesta, Wells, Gentry, & Stipek, 2005), while the Charlson Index of
Comorbidity was used in two investigations (Dial, Alrasadi, Manoukian, Huang, &
Menzies, 2004; Loo et al., 2005). Only Kyne et al. addressed the sensitivity, specificity,
and predictive value of the tool in discussion of the findings.
External validity
Subjects chosen for the studies within this review were described as
representative of the target population in 40 (66%) publications. Twenty studies (33%)
described inclusion criteria for study eligibility and an additional 20 described both
inclusion and exclusion criteria for participation. For this reason, generalization of study
findings to a specific target population is rather limited.
Funding disclosure
Only 13 (21%) publications acknowledged a funding source or study sponsorship
either within the body of the paper or the notes and acknowledgements. This may due to
lack of sponsorship, journal standards and restrictions regarding acknowledgements, or
simply reflective of the period of time in which the studies were published. In the
checklist proposed by Downs and Black (1998), there is no question regarding
sponsorship. However in the 2002 report by West et al. for the Agency for Healthcare
Research and Quality, sponsorship is considered an essential criterion for evaluating
quality. Of the 42 studies published before 2003, only 14% include funding information,
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but 37% of those published in 2003 or later include this information. It is anticipated that
this percent will increase over time as qualitative assessment of research findings
becomes more refined.
Quantitative Assessment of Research Findings
In order to evaluate the strength of the association between specific ecological
variables and the development of CDAD, published odds ratio (O.R.) and relative risk
(R.R.) data were systematically examined similar to the method used in the qualitative
portion of the meta-analysis publication (Bignardi, 1998). When O.R. or R.R. data was
not provided, it was calculated, if possible, from data within the published article.
Evidence supportive of the association of a risk factor with the development of CDAD
was defined either of the following: (1) a statistically significant (p<0.05) positive
univariate O.R. or R.R. in the majority of studies using univariate analysis to evaluate the
risk factor or (2) a statistically significant (p<0.05), positive multivariate O.R. Evidence
was considered non-supportive of an association if it failed to meet either of the above
criteria or if two or more studies using multivariate analysis failed to identify a
statistically significant positive association for the risk factor.
Age
The effect of age upon the development of CDAD in hospitalized populations is
uncertain. Within this body of literature, age has been studied as a confounder, a risk
factor, and an effect modifier. Age is often considered a confounding variable in
epidemiological investigations. Eight studies used matching to control for potential
confounding effects of age, thus eliminating it for consideration as a risk factor for the
development of CDAD (Bliss et al., 1998; Changela et al., 2004; Cunningham, Dale,
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Undy, & Gaunt, 2003; Kreisel, Thomas, Silver, & Cunningham, 1995; Loo et al., 2005;
MacGowan et al., 1997; Thamlikitkul, Danpakdi, & Chokloikaew, 1996; Vesta, Wells,
Gentry, & Stipek, 2005; Yip, Loeb, Salama, Moss, & Olde, 2001). An additional study
did not use matching for age, but selected controls within the same age-range as case
patients, thereby minimizing the possibility of differences in age between cases and
controls (Changela et al., 2004).
Twenty-eight publications included age as a variable in the statistical analysis of
study findings. Eight publications reported statistically significant differences in mean
age between CDAD subjects and non-CDAD comparison subjects within the presentation
of demographic data (Ackermann et al., 2005; Barbut et al., 2005; Buchner &
Sonnenberg, 2002; Climo et al., 1998; Harbarth, Samore, & Carmeli, 2001; Kent, Rubin,
Wroblewski, Hanff, & Silen, 1998; McFarland, 1995; Svenungsson, Lagergren, &
Lundberg, 2001).
Age was evaluated as a specific risk factor for CDAD in 13 studies. Of the five
studies reporting only univariate analysis, four reported statistically significant positive
associations with CDAD (Ackermann et al., 2005; Karlstrom, Fryklund, Tullus, Burman,
& Group, 1998; Kyne, Sougioultzis, McFarland, & Kelly, 2002; Watanakunakorn,
Watanakunakorn, & Hazy, 1996). Increasing age was found to have a statistically
significant positive association in five additional studies using multivariate data analysis
(Andrews, Raboud, Kassen, & Enns, 2003; Chang & Nelson, 2000; Modena, Bearelly,
Swartz, & Friedenberg, 2005; Muto et al., 2005; Starr, Martin, McCoubrey, Gibson, &
Poxton, 2003). Although Harbarth et al. (2001) reported a univariate O.R. of 2.5 with a
significance level sufficient for entry into multivariate analysis (p = .08), age was not
21

entered as a variable in the logistic regression analysis. Only one publication within this
review reported a non-significant association (Kyne et al., 1999). Therefore, the findings
of this review are consistent with those of Bignardi (1998) who reported substantial
evidence for increasing age as a risk factor for CDAD.
A problem noted in comparing research findings regarding this variable is the
disparity in ages considered reflective of advanced age. While some investigations
considered subjects 60 years and older to be geriatric, others used 70 or 75 years as a cutpoint. None of the published studies included information about why a particular age
range was selected as a risk factor for data collection and analysis.
It is likely that age is also an effect modifier for development of CDAD. As age
increases, the likelihood of exposure to toxigenic strains of the organism increases,
principally through institutionalization in a hospital, rehabilitation, or long-term care
setting. Institutionalization will not be investigated as a potential risk factor for CDAD in
the present study because all subjects will be inpatients within an acute care hospital.
Several investigations within this review reported significant differences in CDAD rates
for nursing home versus community-dwelling adults (Al-Eidan, :McElnay, Scott, &
Kearney, 2000; Cooper, Lederman, & Salata, 1995; Kent, Rubin, Wroblewski, Hanff, &
Silen, 1998) . A descriptive study demonstrating a reduction in CDAD within geriatric
wards of several acute care hospitals following implementation of an enhanced infection
control program suggests that infection exposure may play a larger role than age in
disease development (Stone, Beric, Quick, Balestrini, & Kibbler, 1998). Treatment of
chronic illnesses is more common in old age, and acute exacerbations and complications
increase the likelihood of multiple drug exposures, including antibiotics. A significant
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difference has been demonstrated in the mean age of subjects exposed to antibiotics prior
to the development of CDAD and those with no previous antibiotic exposure
(Svenungsson, Lagergren, & Lundberg, 2001). Aging also makes an individual more
likely to be exposed to tube feeding as a substitute or supplement to oral feeding. This
type of artificial nutrition is associated with major changes in fecal flora (Schneider et al.,
2000) and has been identified as a significant risk factor for both acquisition of the
organism and development of CDAD (Bliss et al., 1998; Komatsu et al., 2003).
Acid Suppression
The administration of drugs to suppress or neutralize gastric acid production has
been explored as a biologically plausible risk factor for the development of CDAD.
Bignardi (1998) found substantial evidence for use of “anti-ulcer medication including
antacids and H2 blockers” (p.5). A total of 16 studies were identified which considered
alteration of gastric acid as a risk factor. However, within this review, acid suppressive
medications were examined in three separate categories: antacids, histamine-2 blocking
agents (H2), and proton pump inhibitors (PPI), as each class of drugs has a distinctly
different physiologic mechanism of action.
Antacid medications were studied in six publications. Two were analyzed using
univariate techniques only, while four described multivariate data analysis. Nonsignificant findings were reported for five studies (Aziz, Ayis, Gould, & Rawlins, 2001;
Barbut et al., 1997; Hornbuckle et al., 1998; Kyne et al., 1999; Watanakunakorn,
Watanakunakorn, & Hazy, 1996). Only one of these publications reported statistically
significant positive associations for antacid medication use (Tacconelli et al., 1998).
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Of the nine studies measuring exposure to H2 blocking agents, three reported
non-significant univariate test results (Dial, Alrasadi, Manoukian, Huang, & Menzies,
2004; Loo et al., 2005; Watanakunakorn, Watanakunakorn, & Hazy, 1996) and another
reported non-significant multivariate results (Kyne et al., 1999). A high-magnitude
statistically significant positive association was identified in one univariate study (Yip,
Loeb, Salama, Moss, & Olde, 2001) and a more moderate significant multivariate
association was reported by Muto (2005).
The use of proton pump inhibitor (PPI) agents has generated the most consistent
associations for acid suppressive exposure across studies. Ten publications in this review
assessed the relationship between PPI drugs and CDAD. Three univariate analyses
produced statistically significant positive associations (Al-Tureihi, Hassoun, Wolf-Klein,
& Isenberg, 2005; Cunningham, Dale, Undy, & Gaunt, 2003; Yearsley et al., 2006), but
Kyne (1999) and Loo (2005) both reported non-significance. Two reports indicated
statistically significant multivariate O.R. for PPI exposure (Dial, Alrasadi, Manoukian,
Huang, & Menzies, 2004; Muto et al., 2005).
All of the studies investigating acid suppression as a risk factor for CDAD
measured exposure dichotomously; therefore, a dose response could not be assessed from
this review. No evidence was found to suggest that antacids, which neutralize the pH
level of gastric secretions, are associated with the development of CDAD. However, H2
blockers and PPI agents, which exert an effect at the cellular level and result in a decrease
in acid production, have some evidence to suggest their influence. Future research
should consider these as separate drug categories for data collection, and an attempt
should be made to determine if there is a dose-response for either type of agent.
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Antibiotic Administration
The risk factor for CDAD development investigated the most extensively over the
past thirty years is antibiotic exposure. The scientific literature includes studies of both
the amount of antibiotic exposure associated with CDAD and the specific antibiotics
most likely to be associated with the disease. Although one meta-analysis reported a
significant association between antibiotic exposure and CDAD (Bignardi, 1998), a
systematic review of published epidemiologic studies between 1978 and 2001 identified
threats to internal validity in a majority of the studies due to incorrect control group
selection, inadequate sample sizes, inadequate control of confounders, and
misclassification bias in case identification (Thomas, Stevenson, & Riley, 2003).
The original literature search identified 66 publications in which antibiotic
exposure was considered as a risk factor for the development of CDAD. In addition to a
meta-analysis and structured review, there were 64 original research publications
identified. Of these studies, seven were descriptive and provided no information about
the disease frequency, the role of chance, or the strength of the association (Bulstrode et
al., 1997; Crabtree, Pellitier, Gleason, Pruett, & Sawyer, 1999; Gorecki, Schein,
Rucinski, & Wise, 1999; Impallomeni, Galletly, Wort, Staff, & Rogers, 1995; Khan &
Cheesbrough, 2003; Shek, Stacey, Rendell, Hellier, & Hanson, 2000; Stone, Beric,
Quick, Balestrini, & Kibbler, 1998).
A major difficulty in assessing the strength of evidence regarding antibiotic
exposure as a CDAD risk factor is the multiple ways in which exposure has been
operationalized and measured. More than 25% of the studies measured antibiotic
exposure via more than one method. The most frequently described measure, reported in
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41 papers, and was a simple binary assessment of exposure to a specific antibiotic drug
classification. Twenty-two papers measured any antibiotic exposure, while 12 measured
the number of different drug agents used. Three studies examined specific antibiotic
regimens and two classified antibiotic use as “appropriate” or “inappropriate”.
Surprisingly, only four of the publications attempted to quantify antibiotic exposure by
measuring the number of doses, and only one did so through the use of a standardized
dose measure. A unit of measure, the defined daily dose (DDD), represents the average
daily adult dose for a drug when used for its primary indication (Pelle, Gilchrist, Lawson,
Jacklin, & Franklin, 2006). This measure has been advocated for drug exposure research
by the World Health Organization to facilitate comparisons of drug usage despite
international variations in clinical practice patterns. Only one of the studies included in
this review used the DDD unit for measuring antibiotic exposure, although the system has
been in effect for over 20 years (Al-eidan).
In considering all antibiotic exposure as a whole, study results present conflicting
evidence. Bignardi (1998) reported a pooled O.R. of 5.9 for a binary measure of
antibiotic exposure. One multivariate study published after 1998 (Cunningham, Dale,
Undy, & Gaunt, 2003) and five univariate studies reported statistically significant
positive associations for antibiotic exposure (Blot et al., 2003; Loo et al., 2005; Starr,
Martin, McCoubrey, Gibson, & Poxton, 2003; Svenungsson, Lagergren, & Lundberg,
2001; Yearsley et al., 2006). This provides strong evidence for antibiotic exposure as a
consistent and independent risk factor for CDAD acquisition.
In contrast, four studies published after the Bignardi paper reported nonsignificant multivariate O.R. for this same variable (Chang & Nelson, 2000; Harbarth,
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Samore, & Carmeli, 2001; Loo et al., 2005; McCusker, Harris, Perencevich, &
Roghmann, 2003). Two case-control (Komatsu et al., 2003; Vesta, Wells, Gentry, &
Stipek, 2005) and two prospective cohort studies (Cleary et al., 1998; Kyne,
Sougioultzis, McFarland, & Kelly, 2002) did not enter antibiotic exposure into
multivariate analysis based upon overly stringent bivariate test results. Barbut et al.
(2005) did not include antibiotic exposure in the multivariate analysis due to both low
magnitude and non-significance on univariate testing. In a sample of oncology patients,
antibiotic exposure was associated with CDAD only in patients also receiving
chemotherapy (Blot et al., 2003). Both treatment with any antibiotic and treatment with
specific classes of antibiotics were entered into logistic regression models in a
prospective cohort study, and both failed to demonstrate statistical significance (Bliss et
al., 1998). This discrepancy in findings indicates the need for a more accurate and
quantitative means of measuring antibiotic exposure in future research.
A number of studies did attempt to operationalize the burden of antibiotic
exposure through measurement of the number of different antibiotic agents to which
subjects were exposed. Three studies reported statistically significant differences
between cases and comparison subjects in the mean number of antibiotic agents used, but
these studies did not report measures of association or provide sufficient information
within the publication to calculate these measures (Climo et al., 1998; Kyne,
Sougioultzis, McFarland, & Kelly, 2002; Loo et al., 2005). Pulvirenti et al. (2002A)
reported a statistically significant, positive multivariate O.R. for the number of
antibiotics. Dial et al. (2004) also reported a statistically significant, positive multivariate
O.R.s for the number of antibiotics in a cohort study, but a case-control study reported in
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the same paper did not have statistically significant findings. Statistically significant
positive univariate associations were reported by five other studies (Andrews, Raboud,
Kassen, & Enns, 2003; Harbarth, Samore, & Carmeli, 2001; Lai, Melvin, Menard,
Kotilainen, & Baker, 1997; L. V. McFarland, 1995; J.J. Pulvirenti et al., 2002).
Assessment of antibiotic burden measured based on a simple count of the number
of doses has not yielded clinically important information. No significant difference was
found in the mean number of antibiotic doses received between cases and comparison
subjects in one investigation (MacGowan et al., 1997), and Kyne et al. (1999) reported a
positive, but not statistically significant multivariate O.R. for the number of antibiotic
doses. It would appear that a count of doses administered is not useful in quantifying
antibiotic burden. Al-Eidan et al. (2000) attempted to quantify doses using the Defined
Daily Dose system. However, the number of doses used for each drug were calculated
based upon Pharmacy purchasing data, and were not obtained from individual patient
records. Therefore the actual degree of antibiotic exposure for individual subjects was
not accurately measured.
Within this review, researchers identified a number of antimicrobial drug
categories as exposures associated with CDAD. These findings are summarized in Table
3. Antibiotic agents are grouped by their pharmacologic drug category in column 1.
Studies reporting non-significant associations are listed in column 2, those reporting
statistically significant univariate associations are listed in column 3, and studies
reporting statistically significant multivariate associations are listed in column 4.
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Table 3
Reported Significance of Test Results for Antibiotic Exposure by Drug Category
Significance of the Association with CDAD
Drug Category

Non-significant

+ Univariate

+ Multivariate

Aminioglycosides

Johnson et al., 1999;
Komatsu et al., 2003
Muto et al., 2005
Palmore, Sohn, Malak,
Eagan, & Sepkowitz,
2005
Shah, Lewis, Leopold,
Dunstan, & Woodhouse
Vesta, Wells, Gentry, &
Stipek, 2005
Watanakunakorn,
Watanakunakorn, &
Hazy, 1996
Yip, Loeb, Salama, Moss,
& Olde, 2001

Barbut et al., 1997
Bliss et al., 1998
Changela et al., 2004
Cooper, Lederman, &
Salata, 1995
Halim, Peterson, Friesen,
& Ott, 1997
Harbarth, Samore, &
Carmeli, 2001
Kyne, 2002 Schwaber et
al., 2000*
Talon et al., 1995

Loo et al., 2005*

Penecillins

Aziz, Gould, & Rawlins,
2001
Harbarth, Samore, &
Carmeli, 2001
Johnson
Komatsu et al., 2003
Kyneet al., 1998
Kyne et al., 1999
Loo et al., 2005
McCusker, Harris,
Perencevich, &
Roghmann, 2003
Mody, Smith, & dever,
2001
Palmore, Sohn, Malak,
Eagan, & Sepkowitz,
2005
Shah, Lewis, Leopold,
Dunstan, & Woodhouse
Vesta, Wells, Gentry, &
Stipek, 2005
Watanakunakorn,
Watanakunakorn, &
Hazy, 1996
Yip, Loeb, Salama, Moss,
& Olde, 2001
Dial, Alrasadi,
Manoukian, Huang, &
Menzies, 2004
Johnson et al., 1999
Komatsu et al., 2003
Kyne et al., 199

Al-Eidan, McElnay, Scott,
& Kearney, 2000 et al.,
2000 Changela
Cooper, Lederman, &
Salata, 1995
Dial, Alrasadi,
Manoukian, Huang, &
Menzies, 2004
Rao, Rao, & Starke, 2003
Schwaber et al., 2000
Starr, Martin,
McCoubrey, Gibson, &
Poxton, 2003
Talon et al., 1995

Barbut et al, 1997
Talon et al., 1995

Al-Eidan, McElnay, Scott,
& Kearney, 2000;
Arrango et al., 2006
Barbut et al., 1997
Changela et al., 2004
Cooper, Lederman, &

Aziz, Gould, & Rawlins,
2001
Bliss et al., 1998
Loo et al., 2005
Yip, Loeb, Salama,
Moss, & Olde, 2001

Cephalosporins

29

Table 3 (Continued)
Significance of the Association with CDAD
Drug Category

Non-significant

+ Univariate

Cephalosporins continued

McCusker, Harris,
Perencevich, &
Roghmann, 2003
Mody, Smith, & dever,
2001 (1st generation)
Muto et al., 2005 (1st and
2nd generation)
Palmore, Sohn, Malak,
Eagan, & Sepkowitz,
2005
Vesta, Wells, Gentry, &
Stipek, 2005

Quinolones

Dial, Alrasadi,
Manoukian, Huang, &
Menzies, 2004 (case
control)
Komatsu et al., 2003
Kyne et al, 1998
Kyne, Sougioultzis,
McFarland, & Kelly, 2002
Mody, Smith, & dever,
2001
Muto et al., 2005
(ciprofloxacin)
Palmore, Sohn, Malak,
Eagan, & Sepkowitz,
2005
Rao, Rao, & Starke, 2003
Shah, Lewis, Leopold,
Dunstan, & Woodhouse
Talon et al., 1995
Watanakunakorn,
Watanakunakorn, &
Hazy, 1996

Salata, 1995
Halim, Peterson, Friesen,
& Ott, 1997
Harbarth, Samore, &
Carmeli, 2001
Kyne et al., 1998
Mody, Smith, & dever,
2001 (3rd generation)
Muto et al., 2005 (3rd and
4th generation)
Rao, Rao, & Starke, 2003
Schwaber et al., 2000
Settle, Wilcox, Fawley,
Corrado, & Hawkey, 1998
Shah, Lewis, Leopold,
Dunstan, & Woodhouse
Starr, Martin,
McCoubrey, Gibson, &
Poxton, 2003
Talon et al., 1995’
Tumbarello, Tacconelli,
Leone, Cauda, & Ortona,
1995
Watanakunakorn,
Watanakunakorn, &
Hazy, 1996
Barbut et al., 1997*
Bilgrami et al., 1999*
Changela
Dial, Alrasadi,
Manoukian, Huang, &
Menzies, 2004 (cohort)
Harbarth, Samore, &
Carmeli, 2001
Muto et al., 2005
(levofloxacin)
Pulvirenti, 2002A
Schwaber et al., 2000
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+ Multivariate

Loo et al., 2005
McCusker, Harris,
Perencevich, &
Roghmann, 2003
Yip, Loeb, Salama,
Moss, & Olde, 2001

Table 3 (Continued)
Significance of the Association with CDAD
Drug Category

Non-significant

+ Univariate

Macrolides

Harbarth, Samore, &
Carmeli, 2001
Komatsu et al., 2003
Kyne, 1998
Loo et al., 2005
Mody, Smith, & dever,
2001
Palmore, Sohn, Malak,
Eagan, & Sepkowitz,
2005
Shah, Lewis, Leopold,
Dunstan, & Woodhouse
Watanakunakorn,
Watanakunakorn, &
Hazy, 1996

Changela et al., 2004
Muto et al., 2005
Pulvirenti et al., 2002A
Schwaber et al., 2000

Clindamycin

Dial, Alrasadi,
Manoukian, Huang, &
Menzies, 2004 (casecontrol study)
Komatsu et al., 2003
Kyne et al., 1998
Kyne, Sougioultzis,
McFarland, & Kelly, 2002
McCusker, Harris,
Perencevich, &
Roghmann, 2003
Watanakunakorn,
Watanakunakorn, &
Hazy, 1996
Yip, Loeb, Salama, Moss,
& Olde, 2001
Aziz, Gould, & Rawlins,
2001
Harbarth, Samore, &
Carmeli, 2001
Kyne, 2002
Shah, Lewis, Leopold,
Dunstan, & Woodhouse
Yip, Loeb, Salama, Moss,
& Olde, 2001
Changela et al., 2004
Kyne, Sougioultzis,
McFarland, & Kelly, 2002
Muto et al., 2005
Komatsu et al., 2003
Loo et al., 2005
Muto et al., 2005

Changela
Harbarth, Samore, &
Carmeli, 2001
Johnson
Mody, Smith, & dever,
2001
Muto et al., 2005
Rao, Rao, & Starke, 2003
Schwaber et al., 2000
Thamliktkul, Danpakdi, &
Chokloikaew, 1996
Tumbarello, Tacconelli,
Leone, Cauda, & Ortona,
1995

Sulfonamides

Tetracyclines

Carbapenems

Barbut et al., 1997*
Dial, Alrasadi,
Manoukian, Huang, &
Menzies, 2004
Muto et al., 2005
Schwaber et al., 2000*
Tumbarello, Tacconelli,
Leone, Cauda, & Ortona,
1995

Changela et al., 2004
Harbarth, Samore, &
Carmeli, 2001
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+ Multivariate

Barbut, 1997
Chang & Nelson, 2000
Loo et al., 2005
Palmore, Sohn, Malak,
Eagan, & Sepkowitz,
2005

Table 3 (Continued)
Significance of the Association with CDAD
Drug Category

Non-significant

+ Univariate

Glycopeptides

Johnson et al., 1999
Komatsu et al., 2003
Loo et al., 2005
Mody, Smith, & dever,
2001
Muto et al., 2005
Palmore, Sohn, Malak,
Eagan, & Sepkowitz,
2005
Shah, Lewis, Leopold,
Dunstan, & Woodhouse
Watanakunakorn,
Watanakunakorn, &
Hazy, 1996

Arrango et al., 2006
Barbutet al., 1997
Changela et al., 2004
Dial, Alrasadi,
Manoukian, Huang, &
Menzies, 2004
Schwaber et al., 2000

+ Multivariate

Metronidazole

Kyne, Sougioultzis,
Barbut et al., 1997*
McFarland, & Kelly, 2002 Chakrabarti, Lees, Jones,
Mody, Smith, & dever,
& Milligan, 2000
2001
Dial, Alrasadi,
Palmore, Sohn, Malak,
Manoukian, Huang, &
Eagan, & Sepkowitz,
Menzies, 2004
2005
Pulvirenti et al., 2002A
Watanakunakorn,
Pulvirenti et al., 2002B
Watanakunakorn, &
Schwaber et al., 2000
Hazy, 1996
Wren, Ahmed, Jamal, &
Safadi, 2005
Statistically significant positive O.R. with magnitude > 1.0

Within the penicillin class, results were very varied. Two studies demonstrated
independence for penicillin exposure, and seven demonstrated consistency. The overall
number of studies with non-significant findings, however, outnumbers those with
significant findings. The penicillin class of drugs is one in which successive generations
have been developed in an attempt to avoid drug resistance. For this reason, a simple
grouping of all penicillin’s may not be adequate for epidemiological purposes. Future
research regarding drug classes and exposure should distinguish these groupings in
addition to determining if there is a dose-response to sub-group penicillin.
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Cephalosporin antibiotics were investigated in the largest number of studies. Four
reported independent associations after multivariate analysis, and 17 reported significant
univariate findings, considerably more than the nine that reported non-significant
findings. There is strong evidence to support cephalosporin drug exposure as a risk
factor for CDAD.
Within the quinolone class of antibiotics, there were three studies reporting
independent association with quinolone exposure after multivariate analysis to control for
confounders. There were also seven univariate studies with statistically significant
results. However, the author also reviewed 12 studies that reported negative findings for
quinolone as a risk factor. Future research needs to examine this exposure more fully.
The quinolones represent a clinically important category of antibiotic, and their use as a
risk factor has been investigated in several hospital outbreaks.
Macrolide antibiotics did not have sufficient evidence in this review to consider
them a substantial risk factor in the development of CDAD. There were no studies that
met the criterion of independence, and only four that met the criterion of consistency.
There were seven studies that reported non-significant results for this risk factor.
Not surprisingly, evidence continues to support clindamycin as a risk factor for
CDAD. Although there were seven studies reporting non-significant results for
clindamycin exposure within this body of literature, these studies were overshadowed by
those with significant findings. Four studies reported significant multivariate results and
nine reported significant univariate results for clindamycin exposure.
The category of carbapenems had no reports with multivariate support, and an
even number of reports with significant and non-significant findings. There is not
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sufficient evidence at this time to consider the carbapenems a serious risk factor for the
development of CDAD.
Less than half of the studies that investigated glycopeptide antibiotic use as a risk
factor reported statistically significant univariate measures of association, and there were
no studies with significant multivariate findings. This is not surprising, since
vancomycin, a major glycopeptide used to treat recurrent or resistant CDAD is in this
category of drug. However, the assessment of evidence regarding metronidazole was
unexpected. Metronidazole is considered by many clinicians to be the first line drug used
to treat CDAD cases that fail to respond to withdrawal of antibiotic therapy. Studies with
significant and non-significant measures of association for metronidazole use were
almost equally divided.
The most difficult aspect of evaluating the association of CDAD with antibiotic
exposure is the difficulty in establishing a dose response. Inconsistent methods of
measuring antibiotic exposure complicate comparisons between studies. Median number
of doses given to a specific subject, daily average antibiotic doses dispensed by an
institutional pharmacy, and simple frequency counts of the number of subjects receiving
a particular antibiotic agent have all been used to measure antibiotic exposure. Although
biologic markers, such as serum drug levels, are not available for all antimicrobial drugs,
even when such testing is available, it is not included in published descriptions of
antibiotic exposure, and is not possible in any type of retrospective study.
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Diet
Tube feeding has been investigated as a risk factor for the development of CDAD,
as has malnutrition and hypoalbuminemia. Within this review, 12 studies were located
that examined tube feeding and six considering nutritional deficits as a risk factor.
Tube Feeding. Twelve analytical epidemiology studies were located that
considered tube feeding via either nasogastric or percutaneous abdominal routes as a
potential risk factor for the acquisition of CDAD. A letter to the editor describing data
supporting elemental diets as a risk factor for CDAD was excluded due to lack of details
(Iizuka et al., 2004).
Of the two studies which analyzed data using only univariate analysis, one
reported data sufficient to calculate an O.R. of 2.38 (p<0.05) (Halim, Peterson, Friesen, &
Ott, 1997), and the other reported a non-significant positive association
(Watanakunakorn, Watanakunakorn, & Hazy, 1996). Therefore, satisfaction of the
consistency criterion was unclear.
Ten studies used multivariate data analysis methods. Of these studies, three
evaluated enteral feeding as a variable and determined that it was sufficiently related to
other variables to eliminate for consideration as an independent risk factor (Kyne,
Sougioultzis, McFarland, & Kelly, 2002; Loo et al., 2005; Shah, Lewis, Leopold,
Dunstan, & Woodhouse, 2000). Two studies reported non-significant O.R. (Kent, Rubin,
Wroblewski, Hanff, & Silen, 1998; Yip, Loeb, Salama, Moss, & Olde, 2001), although
the specific values were not published. Four studies found enteral feeding to be an
independent risk factor for CDAD (D. Bliss, Guenter, & Settel, 1992; Buchner &
Sonnenberg, 2001; Komatsu et al., 2003; Talon et al., 1995), and a fifth found enteral
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feeding by nasogastric tube, but not via percutaneously inserted gastrostomy tube (Kyne
et al., 1999) to be independently associated with the disease. Lai reported a statistically
significant negative association between the presence of a nasogastric tube and CDAD.
Enteral feeding appears to be a substantial risk factor for CDAD. However, since this
mode of feeding cannot exist without the presence of the administration tube, the
possibility that enteral feeding is a confounder, rather than a risk factor, should be
considered. Bignardi (1998) identified “nasogastric tubes” as a substantial risk factor, but
did not address enteral feeding. An alternative explanation for the apparent association
between enteral feeding and CDAD has been proposed as “feeding tubes are frequently
given to immune compromised patients with dietary deficiencies and multiple other
comorbid conditions who have spent appreciable amount of time in the hospital. Most
importantly, all percutaneous tubes are inserted under antibiotic
prophylaxis”(Sonnenberg, 2005).
Malnutrition. Of the studies that examined nutritional deficits in association with
CDAD, four used univariate analysis methods only. Of these studies, three reported
statistically significant positive associations between CDAD and malnutrition (AlTureihi, Hassoun, Wolf-Klein, & Isenberg, 2005; Andrews, Raboud, Kassen, & Enns,
2003; Rubin, Bodenstein, & Kent, 1995) as measured by serum hypoalbuminemia. The
other report measured malnutrition via the Prognostic Nutritional Index, a calculation
based on a number of laboratory and clinical factors (Dansinger et al., 1996) and
identified an association between protein-losing enteropathy and CDAD.
Four studies also reported multivariate testing, however the Modena et al. and
Andrews et al. studies omitted entry of the nutritional variable into multivariate analysis
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due to excess missing data points. Buchner and Sonnenberg reported a statistically
significant O.R. of 2.01 for the variable of malnutrition as an independent predictor of
CDAD, but Shah did not report the multivariate O.R., indicating that it was no longer
statistically significant.
The loss of serum protein identified by Dansinger et al. raises important questions
about the relationship between malnutrition, susceptibility to infection, and diarrhea.
This variable should be considered a substantial risk factor for inclusion in future
research.
Cathartic Administration
The impact of laxatives and bowel preparation regimens upon development of
CDAD has not been extensively studies. Among the publications reviewed, six included
data regarding laxative use and one regarding bowel preparation regimens.
A statistically significant R.R. of 3.2 was reported in association with mechanical
bowel preparation among a cohort of surgical patients (McCarter, Abularrage, Velasco,
Davis, & Daly, 1996), This risk factor was not included in the Bignardi list, but most
likely warrants inclusion in future studies.
Six studies investigated laxative use in association with the development of
CDAD. Watanakunakorn et al. (1996) reported a non-significant negative association in
a study of a general hospital population. However, an investigation of CDAD generated
from an HIV-infected population identified a statistically significant positive association
(Pulverenti et al., 2002). Four publications included laxative use in multivariate studies.
Barbut et al. found a negative association between CDAD and laxative use on univariate
testing, but did not include the variable in multivariate analysis, although the p value of
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0.20 would have been sufficient for inclusion in a conditional logistic regression analysis.
Kent et al. (1998) also reported a non-significant p value, and therefore did not include
laxative use in the regression analysis. Kyne et al. (1999) reported a non-significant
negative association. Only one paper reported statistical significance after multivariate
analysis, but it was a negative association for both the general drug category of
“laxatives” as well as the specific agent lactulose (Shah, Lewis, Leopold, Dunstan, &
Woodhouse, 2000).
Laxative use does not appear to increase the risk of CDAD. It is possible that
laxative use may exert a protective effect upon the bowel by facilitating the elimination
of potentially toxigenic organisms. It may, however, serve as a confounder in studies in
which subjects are selected based upon hospitalized persons who have stools submitted
for laboratory testing due to loose or diarrheal stools. Bowel preparation is associated
with CDAD in surgical patients, but this needs more study to determine if the association
is consistent across more populations.
Severity of Illness
The immune response to infectious agent exposure can be impaired by a variety
of mechanisms, including disease and injury. A number of investigations have explored
the concept of severity of illness in association with the development of CDAD. A total
of 22 studies were included in the review that explored the association between
concomitant illness or injury and CDAD. The concept was operationalized in a variety of
ways, including comorbidity, stage of illness, hospital length of stay, intensive care unit
stay, and a severity of illness index (Horn & Horn, 1986).
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The most frequently used method used to measure severity of illness within this
group of studies was comorbidity. Five studies considered the presence or absence of
specific diseases as a measure of comorbidity. Significant positive univariate
associations were reported for chronic renal failure (Cunney, Magee, McNamara, Smyth,
& Walshe, 1998; Harbarth, Samore, & Carmeli, 2001) and renal insufficiency (Rubin,
Bodenstein, & Kent, 1995). Although Yip et al. (2001) reported a non-significant
univariate O.R. for renal failure, the magnitude association was 7.0. Dial et al. also
reported a significant positive multivariate O.R. of 4.3 for chronic renal failure. Other
statistically significant positive univariate associations have been reported for
gastrointestinal illness and anemia (Harbarth, Samore, & Carmeli, 2001), chronic
obstructive pulmonary disease (Rubin, Bodenstein, & Kent, 1995) and malignancy
(Rubin, Bodenstein, & Kent, 1995; Yip, Loeb, Salama, Moss, & Olde, 2001).
Andrews et al. (2003) reported a significant positive multivariate O.R. for
increasing number of organ systems affected by comorbid illness. Two reports indicated
a statistically significant difference in the number of diagnoses between CDAD cases and
controls (Buchner & Sonnenberg, 2001; Mody, Smith, & Dever, 2001), but measures of
association were not reported. Likewise, Buchner and Sonnenberg reported statistically
significant differences in the number of medical and surgical procedures performed on
cases versus controls.
A problem common to all of these studies is the fact that there between subjects,
there may be a great deal of variation in the impact in which a medical diagnosis makes
on the overall health of the individual. Therefore, a diagnosis category, or a count of
diagnoses, is not a valid measure of comorbidity. When a standardized measure, the
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Charlson Index of comorbidity, was used to assess differences between CDAD cases and
a comparison group, no significant differences were found (Loo et al., 2005).
The stage of illness for Human Immunodeficiency Virus (HIV)-infected adults
was examined in two separate studies. Although Pulverenti et al. (2005) found positive
associations through progressive stages of HIV infection, these associations were not
statistically significant on univariate analysis. However, low CD4 cell count has been
significantly associated with CDAD in univariate analysis (Tacconelli et al., 1998), and
both a history of opportunistic infection (Pulverenti et al., 2005) and a CD4 count below
50 mm3 (Barbut et al., 1997) have been reported to have statistically significant positive
associations following multivariate analysis. These findings provide biologically
plausible support for immunosuppression, manifested by both opportunistic infection and
a decline in CD4, as a factor in the causation of CDAD.
The length of hospitalization is significantly longer for persons who develop
CDAD (Buchner & Sonnenberg, 2002; MacGowan et al., 1997; Pulverenti et al., 2002).
However, length of stay data does not indicate whether the prolonged hospitalization is a
risk factor or a consequence of CDAD. Three studies suggest that a prolonged hospital
stay increases risk for the disease. Significant positive multivariate associations have
been reported for prolonged post-operative hospital stay (Harbarth, Samore, & Carmeli,
2001), hospitalization greater than or equal to eight days during a risk period (Pulvirenti
et al., 2002), and hospitalization more than ten days in the month preceding infection
(Pulvirenti et al., 2002). Although an increasing length of stay increases exposure to
microbes in the environment, its sensitivity and specificity as a measure of CDAD risk is
uncertain. It may represent a confounder, rather than a risk factor.
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Modena et al. defined severity of illness in terms of both mechanical ventilation
and the need for care within an intensive care unit (ICU) (2005). Mechanical ventilation
use had a significant positive association with CDAD in univariate analysis and an ICU
stay was statistically significant in multivariate analysis. This categorical data lacks
precision. Like length of hospital stay, it may represent a confounding variable rather
than a risk factor.
McFarland (1995) provided the earliest publication in this review to use the Horn
Severity of Illness Index as a measure. Statistically significant differences in severity
index score were reported within the publication. Relative risks calculated from
published data found a statistically significant positive association for the catastrophic
level of illness, but not for the severe level. Kyne (2002) reported statistically significant
positive associations for both the catastrophic and severe levels of illness. Kyne also
examined the predictive value of the instrument with a score of three or more and
reported sensitivity 79-87, specificity 39-73, positive predictive value 11-27 and negative
predictive value 96-97. More recently, Vesta (2005) published study data that enabled
calculation of a statistically significant O.R. of 7.67 for catastrophic illness. There is
strong evidence that illness that weakens the body’s immune system increases the risk of
CDAD. Although still a categorical measure of severity of illness, the Horn Index
presents a more precise measure of risk than a simple binary variable.
Use of a measure such as the Horn index is more appropriate in the development
of an ecological model for the study of CDAD that is relevant to nursing practice. Such
an instrument attempts to quantify the human response to illness, rather than labeling the
disease process.
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Ecological Model for Study of CDAD
The conceptual model for this study is derived from a model created for the study
of ecosystems as they affect human health (Koren & Crawford-Brown, 2004). This
model considers the macroenvironment, the external environment within which a
potential host functions, and the microenvironment, the physiological factors that alter
the susceptibility of the host.
The movement of human beings within the healthcare setting creates
environmental stressors that can lead to contact, or exposure, between a potential host
and a potentially infectious microorganism. Exposure, however, does not automatically
result in disease for several reasons. First, the amount of exposure an individual sustains
is influenced by the degree of temporal and spatial distance between the area of
contamination and the human being. Extrinsic risk factors, such as antibiotic usage
policies, infection control compliance, and the use of standardized cleaning procedures
are designed to increase the temporal and spatial distance between microorganisms and
humans. Second, and perhaps more importantly, the host response is dependent upon
intrinsic factors that modulate the immune response through changes in the
microenvironment. In the case of CDAD, specific factors known to have substantial
evidence for an association with CDAD are severity of illness, changes in the microflora
of the gut due to aging, antibiotic or chemotherapy usage, use of enteral feeding systems,
malnutrition, gastric acid suppression, and preoperative bowel preparation regimens. An
exposed individual will respond to Clostridium difficile exposure by forming antibodies,
becoming an unprotected carrier, or by developing active Cd infection in varying degrees.

42

HUMAN ACTIVITY WITHIN HOSPITAL MACROENVIRONMENT
Environmental cleaning and disinfection
Movement of healthcare workers
Visitation
Admission of patient
ENVIRONMENTAL STRESSORS
Environmental contamination with Clostridium difficile organism
EXPOSURE
ENVIRONMENTAL SYSTEMS AFFECTING HOST RESPONSE
Extrinsic
Intrinsic
Severity of illness
Spatial and temporal distance from
Age
microorganisms influenced by:
Antibiotic exposure
Antibiotic restriction policies
Enteral feeding
Infection control compliance
Malnutrition
Tube feeding systems
Cathartic administration
Persistence of spores
Gastric acid suppression

Protected
Carrier

RESPONSE TO EXPOSURE
Infection Continuum
Unprotected
Persistent
Mild CDAD
Carrier
CDAD

PMC

EXCRETION
Figure I. Model for the study of ecological variables affecting development of
Clostridium difficile-associated diarrhea.
This study will focus only on the portion of the model that considers the intrinsic
and extrinsic factors that affect a host response to Cd exposure. Because the Cd organism
can persist in an environment for prolonged periods of time in its spore state, reliance
solely upon extrinsic environmental factor to stop the infection may not be sufficient.
Despite nearly two decades of widespread use in the developed world of personal
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protective equipment for the handling of all potentially infectious material, as well as
national campaigns to promote handwashing and judicious antibiotic usage, outbreaks of
CDAD continue. Therefore, an alternative means of identifying the most susceptible
hosts and providing ecologically based care may present of more effective means of
controlling this disease.
Summary
This review of literature has identified ecological variables that affect the
response of a hospitalized adult exposed to the Cd organism. These variables will be
used in the design of a case-control study to identify an ecological model useful for
nurses. These variables include age, antibiotic exposure, bowel preparation, enteral
feeding, malnutrition, gastric acid suppression, and severity of illness.
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Chapter Three
Research Methods
Research Design
The purpose of this study was to develop and test a predictive model for the
development of Clostridium difficile-associated diarrhea. It is anticipated that such a
model can serve three purposes: (1) serve as a foundation for development of a valid and
reliable risk assessment tool (2) aid in the design of future clinical trials of nurse-directed
prevention strategies, and (3) assist clinicians in modifying infection control practices in
institutional settings when caring for high-risk individuals. The study used a case-control
design to develop a predictive model to identify ecological risk factors most closely
associated with the development of hospital-acquired Clostridium difficile associated
diarrhea.
Setting
The setting was a Veteran’s Administration Medical Center located in the
state of Florida. The Medical Center is a 327 bed tertiary care teaching hospital,
with 300 additional authorized nursing home care beds and serves an estimated
population of 435,442 veterans. The full range of inpatient and outpatient care is
provided including Medicine (111 beds), Surgical (61 beds), Psychiatry (50 beds),
Neurology (7 beds), as well as a 60-bed Spinal Cord Injury Service, and a 38-bed
Comprehensive Rehabilitation Center. The center also provides a number of
outpatient clinics on site and at satellite locations.
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The Center is affiliated with a University College of Medicine and
provides residency training programs in the following specialties: Internal
Medicine, Orthopedics, Hematology, Pathology, Radiosurgery, Ophthalmology,
Dermatology, Podiatry, Neurology, Neurosurgery, Urology, Nephrology, General
Surgery, Otolaryngology, Psychiatry, Radiology.
Sample
The study sample consisted of 66 cases and 66 matched controls for a total of 132
subjects. Cases and controls were selected from the electronic medical record database of
the study site medical center. Electronic medical records generated between January 1,
2000 and December 31, 2006 were utilized. Figure 2 illustrates the sequential steps used
in selecting the cases, selecting potential controls, and matching controls to cases.
A total of 1,739 medical records were selected by data mining the medical records
database. Criteria specified for the data mining were
(1) inpatient hospital admission between January 1, 2000 and December 31, 2006
and
(2) laboratory studies for Clostridium difficile cytotoxin assay, total lymphocyte
count, serum albumin, and serum pre-albumin level documented during this time frame.
Of the 1,739 records, 330 were selected as potential cases from the original group
because they also had a medical record diagnostic coding for Clostridium difficile
associated diarrhea. Within this set, 155 records were identified which met the inclusion
criteria of hospital acquired infection as defined by a diagnosis made > 2 days after
hospital admission and < 31 days after hospital discharge, the cut-points selected for
determination of a hospital-acquired CDAD.
46

1,737 records selected for screening based on presence of laboratory testing for
Clostridium difficile, serum albumin, serum prealbumin and total lymphocyte count
between January 1, 2000 and December 31, 2006.
330 records selected for further
screening with diagnostic coding for
CDAD

1,636 records selected for further
screening using criteria of “no
positive Clostridium difficile test

155 records with diagnostic code
entered ≥ 2 days after admission and
≤ 31 days after discharge

Temporal matching. Records
selected if hospital admission date +
31 days of one or more cases

106 records met diagnostic criteria
for SHEA and had no
documentations of any medical
conditions specified for exclusion
from study

Spatial matching. Records selected
if admission unit OR unit with
greatest length of stay matched one
or more cases.

6 records deleted due to sub-acute
stay > 150 days for total of 100
potential cases

Potential matches screened for
presence of diarrhea, absence of
other diagnostic testing suggestive of
CDAD and absence of the exclusion
criteria

66 cases matched 71 controls, with 4 controls each
matching 2 different cases
Controls with admission date closest to case
selected for final sample
• 66 cases
• 66 controls
Figure 2. Sample selection process.
The set of 155 medical records was examined to determine if the record was
consistent with criteria for CDAD case definition outlined in the Shea Position Paper
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(Gerding, Johnson, Peterson, Mulligan, & Silva, 1995). These criteria were (1) diarrhea
(2) documented concurrently or within 7 days of a positive result on one or more of the
following diagnostic tests:
•

Endoscopy with confirmation of pseudomembranous colitis

•

Stool culture for toxigenic strain of C. difficile

•

Cell culture cytotoxin test

•

EIA toxin test

To reduce selection bias that might occur in persons tested for C. difficile due to
recurrence of diarrhea following a previously diagnosed infection, cases were excluded if
the database included a diagnosis of CDAD within 12 months preceding the positive test
result. Because persons with chronic diarrhea referred for stool testing may experience
colonization with C. difficile and might be easily misclassified, cases were also excluded
if there was a history of any of the following: surgical removal of sufficient bowel to
result in chronic diarrhea, chronic ulcerative colitis not previously subjected to surgical
cure, Crohn’s disease, diarrhea-predominant irritable bowel syndrome, or diabetic
neuropathy with chronic diarrhea.
The screening process identified 106 medical records that qualified for inclusion
in the study. Because the focus of the study was acquisition of CDAD during acute care
hospitalization, records also were examined for length of stay in sub-acute areas of the
institution. Six records were discarded due to sub-acute length of stay in excess of 150
days. This yielded a final set of 100 cases.
A total of 1,636 records in the Access database were screened for selection of
controls. These 1,636 records were based on a query to identify records that never
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recorded a positive C. difficile assay. Because ecological disease models consider both
temporal and spatial distance to be a factor in the spread of communicable disease,
controls were matched to cases by hospital admission date and geographic unit of
hospital. For purposes of matching, when a record indicated that the subject was treated
in more than one unit, the unit with the longest length of stay was used for spatial
matching. To select the potential cases, records were first matched based on admission
date + 31 days using an Access query. Records were then manually inspected to match
potential controls to cases by admission unit or unit with the longest length of stay.
Records that matched a case for both admission date and geographic unit of the hospital
were reviewed to ensure presence of the following: (1) diarrhea documented within 7
days of the Clostridium difficile assay test, and (2) absence of both endoscopy and stool
culture results indicative of CDAD. A total of 71 records were identified as matches.
Within the 71 records, there were 4 duplicate matches. To enable a 1:1 matching, the
control record that most closely matched the case record admission date was selected for
the study.
Measurement of Variables
Age
Age of subjects was recorded as the chronological age in years, on the date of
hospital admission.
Nutritional Status
Nutritional status was measured through use of three continuous variables: serum
albumin, serum prealbumin, and lymphocyte count. Laboratory values were recorded
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only for specimens collected within seven days of hospital admission. Laboratory
reference ranges for these tests at the research site are identified in table 4.
Table 4
Laboratory Reference Ranges for Nutritional Indicators
Test

Low

High

Pre-Albumin (mg/100 ml)

18

45

Albumin (mg/100 ml)

3.8

4.8

Lymphocyte count (109/L)

1.1

3.4

Antibiotic Burden
Antibiotic burden was calculated for each subject by antibiotic agent, as a
numerical sum of all Defined Daily Doses. The Defined Daily Dose is the assumed
average maintenance dose per day for a drug when it is used for its main indication in
adults with normal organ function. This measure was developed for the World Health
Organization (WHO) Collaborative Centre for Drug Statistics Methodology to enable
measurement of drug consumption independent of formulation or price. All DDD
calculations were calculated using the WHO index on the world-wide web at
http://www.whocc.no/atcddd/. For each antibiotic agent administered, data was recorded
from the electronic record regarding the prescribed dose of the drug and the number of
doses admininstered during the length of the exposure period (hospital admission to date
of CDAD testing). These prescribed doses were then converted to DDD units, and a sum
of the DDD units was computed for each drug. The drug burden for each subject was the
sum total of all DDD’s for all antibiotic agents.
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Laxatives and Bowel Preparation Medications
Use of any cathartics administered orally or via a feeding tube for either (a) bowel
cleansing regimens prior to surgical or endoscopic procedures or (b) prevention or
treatment of constipation were recorded in a manner similar to antibiotics, and a DDD
was calculated for each subject. Bowel preparations were excluded if there was
documentation in the medical record indicating administration for a diagnostic procedure
to identify pseudomembranous colitis in an individual believed infected with Cd.
Gastric Acid Suppression
Gastric acid suppression was measured for each subject by drug, dosage, dosage
units, and number of dosages administered between the date of hospital admission and
the date a stool sample was submitted for CDAD testing. This information was then
converted to Defined Daily Doses (DDD), and a sum of the DDD units was computed.
For comparison purposes, drugs classified as proton pump inhibitors and those classified
as histamine-2 blocking agents were recorded separately and DDD units were calculated
as separate categories.
Enteral Feeding
Enteral feeding was measured by the number of days in which a nasogastric,
nasoenteral, or percutaneously inserted enteral feeding tube was used to provide
nutritional support between the date of admission and the date a stool sample was
submitted for CDAD testing.
Severity of Illness
Severity of illness level was assigned by the principal investigator using the
Severity of Illness index (Horn & Horn, 1986). This index is an instrument designed to
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create a generic measure, independent of clinician practice patterns, which quantifies a
patient’s illness severity based on retrospective review of records at the time of discharge.
The index groups patients within a four-level ordinal scale, with one representing the
least severe and four the most severe illness. The scale is applied to seven different
dimensions: stage of principal diagnosis, complications, interactions, dependency, nonoperative procedures, the rate of response to therapy, and the degree to which acute
symptoms are resolved at the time of discharge and the overall severity score is the modal
score for the seven categories. Data from 18 different hospitals found an overall
weighted interrater reliability of 93.5%. The index has been found to explain 69-87% of
the variability in resource use within Diagnostic Related Groups (DRGs) and when used
to adjust for DRGs predicts 61% of the variability in cost per case. Kyne et al. (2002)
reported a sensitivity of 87, specificity of 39, positive predictive value of 11 and negative
predictive value of 97 for a Horn’s index of 3 or more (severe or catastrophic illness)
when used with a cohort of hospitalized adult patients receiving antibiotics. In a second
cohort used to validate the model, the team reported sensitivity of 79, specificity of 73,
positive predictive value of 27 and negative predictive value of 96.
Procedures
Approvals
Approval to conduct this study was obtained from the University of South Florida
Institutional Review Board and the James A. Haley VAMC Human Subjects Research
and Development Committee. Request was obtained from both boards to waive informed
consent. To protect the privacy of all subjects, electronic medical records were deidentified prior to the start of data collection. A member of the medical staff of the
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VAMC, who served on the dissertation committee, performed downloading of potential
records into an Access database prior to accession by the principal investigator. Each
record was then assigned a unique pointer number that was a computer-assigned
sequential number, having no association with identifying data. A code-breaking log of
subjects was retained by the VAMC employee within a locked office in a secured area of
the medical center until data collection and analysis was completed. The log was then
destroyed according to VAMC procedures.
Validation of Data Collection Procedure
At the start of data collection, a sample of ten electronic medical records was
selected and data recorded using an Excel workbook developed by the principal
investigator. To validate the accuracy of the principal investigator (PI) in use of the
electronic medical record system, the VAMC co-investigator also reviewed the same
records. The workbook of the PI and co-investigator were compared for concordance of
data elements. All discrepancies between the data were clarified and reviewed until
100% concordance was obtained between the two sets of data. The PI then developed
data collection reference guidelines to ensure consistency during the remainder of the
data collection process.
Data Collection
All data were retrieved from the electronic medical record and recorded in an
Excel workbook developed by the principal investigator based upon a paper worksheet
previously approved by the dissertation committee. The worksheet listing all data
elements collected is in Appendix A. The written data collection reference guide is found
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in Appendix B. All medical record data was recorded under the unique identifier number
developed in the initial data-mining operation.
Data Analysis
The Statistical Package for Social Sciences (SPSS), version 15 software was used
for all data analysis. Initial inspection of data revealed missing values for the variables
prealbumin and albumin. Because more than one-third of the subjects were missing
prealbumin data, this variable was not utilized in the statistical analysis. Missing values
for albumin were imputed by use of the mean for each group.
Cross tabulation revealed that 25% of the cells for the variable severity of illness
included fewer than 5 subjects. To increase power of the analysis, the four categories of
the severity of illness variable were collapsed into two: mild/moderate and
severe/catastrophic. However, this process resulted in 31 uninformative pairs, and the
decision was made to retain all four categories of severity of illness for the remainder of
the data analysis.
Data were entered into SPSS as a sample of 66 pairs, with the cases coded as 1 for
outcome and controls coded as 0. For each covariate, the difference between case and
control values was computed, and the difference scores were used as the covariates in
performing logistic regression analysis (Hosmer & Lemeshow, 2000). Conditional
logistic regression was then performed using the Cox regression procedure, with data
stratified by the matched pairs. Both univariate and multivariate logistic regression
analysis were performed for all covariates using a forced entry method.
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Chapter Four
Results
This chapter presents the findings from the study. Following description of the
cases and controls, results of analytical testing, including the logistic regression
modeling, is presented.
Sample
The data mining and screening process yielded a sample of 66 pairs matched for
admission date and geographic location within the hospital. The sample was 98% male
(64 cases and 65 controls), consistent with the veteran population from which the sample
was selected. The age range for cases was 46.48 to 88.6 years, while control age range
was 31.4 to 90.7 . The majority of the sample had exposure to antibiotic (83%) and
proton pump inhibitor (65%) drugs, however there was limited exposure to tube feeding
(17%) and histamine-2 blocking agents (14%) in this sample. Subjects were treated in a
variety of patient care units within the institution, with the majority of the matched pairs
treated in medical-surgical units, rather than critical care or rehabilitation oriented
setttings.
Subjects were classified in all categories of severity of illness, with the largest
portion (45%) classified as having moderate illness and a third of the sample (33%)
experiencing major illness. Although only 6 subjects (16%) experienced catastrophic
illness, 4 of these 6 subjects were classified as cases.
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Approximately half the sample had lymphocytopenia, present in a slightly higher
percentage of cases (59%) than controls (45%). Hypoalbuminemia was present for 58%
of both groups. Lymphocyte count and serum albumin values correlated significantly
(Spearman’s rho= .409, p<.01).
A comparison of means was computed for all continuous variables via paired ttests. There was a statistically significant difference between means (p<.01) for all
variables except histamine 2 burden and tube feeding days. Tube feeding days was
significant at p<.05, and histamine 2 burden was non-significant. Table 5 identifies the
variables, means and results of the paired testing for each of these variables.
Table 5
Comparison of Case and Control Means Scores on Continuous Predictors
Cases
Controls
(n=66)
(n=66
Predictor
t
Length of exposure/risk period
17.65
24.77
-9.80

p
.000

Laxative/bowel prep burden

6.68

6.12

-3.43

.001

Proton Pump Inhibitor burden

8.81

15.56

-7.53

.000

Histamine 2 burden

2.02

1.29

-2.94

.769

Antibiotic burden

16.95

15.42

-6.70

.000

Tube feeding days

4.12

4.97

-2.17

.032

Serum albumin

3.72

3.58

-30.93

.000

Total lymphoncyte count

1.24

1.12

4.25

.000

Age

68.47

71.27

-66.77

.000

Temporal and Spatial Clustering
Examination of the number of cases by unit by month revealed no patterns
suggestive of an institution-wide outbreak during the time frame of the study. There
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were 7 instances of temporal and spatial clustering of cases identified. Four of the 7
clusters occurred on the same medical nursing care unit. All of the clustering occurred
during the months of March through August in different years. This temporal and spatial
clustering underscores the importance of the macroenvironment in the spread of this
disease.
Univariate Analysis
Table 6 illustrates results of the univariate logistic regression for host,
microenvironmental and macroenvironmental characteristics for both cases and controls.
Table 6
Sample Description and Predictors of Hospital Acquired CDAD
Group
Univariate logistic regression
Total
Characteristic

(N=1
32)

Controls Cases
(n=66) (n=66)

OR

95% CI
Lower Upper

p

Host characteristics
Age (years)
M
SD
Severity of illness
% minor illness
% moderate illness
% major illness
% catastrophic illness
Serum albumin (mg/dl)
M
SD
% hypoalbuminemic
Lymphocytes
M
SD
% lymphocytopenic

69.87
11.69

71.27
10.28

68.47
12.88

1.013

.997

1.029

.124

16.67
45.45
33.33
4.54

25.76
54.55
16.67
3.03

7.58
36.36
50.00
6.06

1.845

1.322

2.574

.000

3.65
0.73
57.58

3.65
0.72
57.58

3.65
0.74
57.58

0.863

.752

.989

.034

1.18
0.74
52.27

1.12
0.77
45.45

1.24
0.72
59.09

0.915

.735

1.139

.424

.999

1.018

.085

Macroenvironmental characteristic
Length of exposure (days)
M
SD

21.21
23.03

24.77
26.21
57

17.65
18.87

1.008

Table 6 (Continued)
Total
(N=1
32)

Characteristic

Group
Controls
(n=66)

Cases
(n=66)

Univariate logistic regression
OR

95% CI
Lower Upper

p

Microenvironmental exposure characteristics
Laxatives/preps
M
SD
% exposed (>1DDD)
Proton pump inhibitors
M
SD
% exposed (>1DDD)
Histamine 2 blockers
M
SD
% exposed (>1DDD)
Antibiotic burden
M
SD
% exposed (>1DDD)
Tube feeding (days)
M
SD
% exposed (>1day)

6.40
16.44
31.82

6.12
15.98
31.82

6.68
17.01
31.82

.999

.989

1.009

.851

12.18
18.20
65.15

15.56
21.72
65.15

8.81
13.13
65.15

1.017

1.002

1.032

.023

1.65
5.98
14.39

1.29
4.22
15.15

2.02
7.35
13.64

.990

.961

1.020

.516

16.18
25.14
78.03

15.418
24.642
72.73

16.95
25.804
83.33

1.002

.994

1.010

.684

4.55
16.10
17.42

4.97
17.37
16.67

4.12
14.85
15.15

1.002

.991

1.012

.768

This analysis identified age, severity of illness, serum albumin level, length of exposure,
and proton pump inhibitor drug burden as statistically significant predictors of case status
(p<.25).
Multivariate Analysis and Model Evaluation
Conditional logistic regression analysis via a Cox regression procedure was used
to identify predictor variables significantly associated with classification of CDAD case
status. Following an initial modeling process, only three variables remained as
significant predictors of case status: severity of illness, antibiotic exposure, and length of
exposure/risk period. Table 7 presents the results of the conditional logistic regression
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modeling. Increased severity of illness, a decrease in the number of Defined Daily Doses
of antibiotic, and an increase in the length of hospitalization prior to symptom
development were all significantly associated with CDAD case status. The overall model
was significant at p=.000.
The calculated Hosmer and Lemeshow estimation of R2 was 25.274, indicating
that the model explains approximately 25% of the variance in CDAD outcome. It should
be noted, however, that “low R2 values in logistic are the norm” (Hosmer & Lemeshow,
2000, p.167).
Table 7
Conditional Logistic Regression of Variables Predictive of CDAD Case Status
Variable
B
Wald
p
OR
95% CI
Severity of illness

.739

13.506

.000

2.094

1.412, 3.106

Antibiotic exposure

-.021

6.007

.014

.979

.962, .996

Length of exposure
.022
5.933
.015
1.022
1.004, 1.040
2
2
Note: R = 25.274 (Hosmer & Lemeshow). Model χ = 23.123, p=.000. OR= Odds
Ratio, CI=Confidence Interval.
As covariates were removed from the model, the Odds Ratios (OR) for all other
covariates remaining in the model were examined to determine if there was a large
magnitude in the change of the OR which might indicate confounding. Only one
clinically significant change was noted. Both albumin and lymphocyte count appeared to
serve as slight confounders for the measure of severity of illness, although the magnitude
of the change in the severity coefficient was small for each variable(5% for serum
albumin, 3% for lymphocyte count).

59

Following the identification of the initial model, a number of interactions were
tested via forced entry. Potential interactions were identified for numerous combinations
that might be clinically important related to age, serum albumin, antibiotic drug burden,
and the length of exposure/risk period. Table 8 lists the interactions tested and the
outcome of each test. None of these interactions was found statistically signficant.
Table 8
Conditional Logistic Regression of Interaction Effects as Predictors of Case Status
Interaction

B

Wald

p

OR

95% CI

Age x Antibiotics

-.021

.076

.783

.980

.846,1.135

Age x Albumin

.156

.018

.893

1.169

.120, 11.414

Age x Lymphocytes

.116

.008

.927

1.123

.094, 13.432

Age x Laxatives

.000

.034

.853

1.00

1.00, 1.00

Age x Proton pump inhibitor

.031

.076

.783

1.031

.8289, 1.283

Age x Length of exposure

-.015

.038

.846

.985

.844, 1.149

Albumin x Lymphocyte

2.520

.018

.893

12.431

.000, 1E+017

Albumin x Proton pump
inhibitor

.426

.376

.540

1.532

.392, 5.984

Albumin x Length of exposure

-.194

.076

.783

.824

.207, 3.275

Antibiotics x Albumin

-.425

.250

.617

.654

.123, 3.460

Antibiotics x H2 blockers

-.076

.403

.526

.926

.732, 1.173

Length of exposure x
Lymphocytes

-.195

.038

.846

.823

.116, 5.859

Age x H2 blocker
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DFBeta residuals were examined to identify data points that may have been
unduly influential for a particular covariate or which did not fit the model well. All of
these residuals were very small (< 0.06).
Collinearity was assessed via generation of a matrix of correlations, using the
non-parametric Spearman rho. Statistically significant correlations were all of low
magnitude (<.50) except for the correlations between length of exposure with antibiotic
burden (.541, p=.000) and tube feeding days with antibiotic burden (.513, p=.000).
Collinearity diagnostics in the linear regression function revealed no tolerance values <
0.1 and no VIF values > 10, indicating that there were no serious problems with
collinearity caused by these correlations.
Receiver Operator Characteristic (ROC) curves were generated for each of the
predictors in the model. Figure 3 illustrates the plot of sensitivity versus 1-specificity for
the Severity of Illness index for all possible cut points. The area under the curve is .776,
indicating an acceptable level of discrimination. The area under the curve for length of
exposure was less acceptable at .620. The plot for antibiotic burden was nearly nondiscriminatory with an area under the curve of .537.
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Hypothesis
The study originally hypothesized that severity of illness, length of exposure and
malnutrition are significant predictors of CDAD cases status when cases and controls are
matched for admission date, and geographic unit of hospital, and after controlling for the
effects of age, tube feeding, cathartic administration, antibiotic therapy, and acid
suppression therapy. This sample suggests that both severity of illness and length of
exposure are significant predictors, but that malnutrition estimated by two laboratory
indicators, serum albumin and lymphocyte count, is not an accurate predictor. It was
anticipated that antibiotic exposure might represent an effect modifier, rather than a
predictor. However, antibiotic exposure, quantified by cumulative Defined Daily Doses
was identified as a significant independent predictor of CDAD case status and failed to
demonstrate any interaction effects when tested in combination with a number of
biologically plausible covariates.
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Chapter Five
Discussion
The purpose of this study was to test an ecological model for its usefulness in
predicting the development of Clostridium difficile-associated diarrhea in hospitalized
adults. This chapter discusses the findings of the study, conclusions about the findings,
limitations of the study, and implications for nursing practice and education, as well as
future nursing research.
Based on an ecological model, it was hypothesized that severity of illness, length
of exposure and malnutrition would significantly predict the development of CDAD case
status when cases and controls are matched for admission date, and geographic unit of
hospital, and after controlling for the effects of age, tube feeding, cathartic
administration, antibiotic therapy, and acid suppression therapy.
Severity of Illness
Although the portion of the sample rated as catastrophic on the Severity of Illness
Index was less than 20%, the portion of cases rated as catastrophic was double that of
controls. An even greater disparity was observed in the category of major illness, with
50% of cases and only 16.67% of controls exhibiting characteristics of major illness.
More than 80% of controls fell into either moderate or minor severity of illness
categories, but only less than 45% of cases were similarly ranked.
Severity of illness was identified as a statiscally significant independent predictor
of CDAD case status for this sample following conditional logistic regression analysis.
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This finding is consistent with previous studies using the Horn Severity of Illness index
(McFarland, 1995; Kyne, 2002; Vesta, 2005). Likewise, it is consistent with the work of
Modena (2005) who characterized severity in relation to events such as mechanical
ventilation and ICU utilization, criteria that are part of the Horn Severity index.
Length of Exposure
Length of exposure was defined as the number of days which elapsed from the
date of hospital admission until the submission of a stool sample for Clostridium difficile
laboratory testing. This variable was derived for this study from the ecological model
specifying extrinsic ecologic factors affecting infectious disease exposure. Based on the
model, both temporal and spatial distance must be increased to prevent the transmission
of microbial contaminants to susceptible hosts. Previous researchers have considered
length of total hospital stay as a variable, but this was studied primarily as a proxy for
severity of illness. The author is unaware of previous studies considering temporal
distance as a risk factor for acquisition of this disease.
In this study, there was a statistically significant difference between the mean
length of exposure for cases and controls (17.65 versus 24.77 days). Length of exposure
was also identified as a statistically significant independent predictor of CDAD case
status following multivariate modeling. Specifically, the longer a subject had been
hospitalized prior to the development of diarrhea and subsequent stool sample collection,
the more likely that the diarrhea was caused by Clostridium difficile.
Malnutrition
This study attempted to operationalize malnutrition by means of three commonly
available laboratory tests: serum albumin, lymphocyte count, and serum prealbumin.
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Since immunocompetence is partially dependent upon positive nitrogen balance and
intake of essential vitamins and minerals, it was hypothesized that malnutrition,
evidenced by values below the laboratory’s reference values, would be associated with
CDAD status. Although the original data mining process used prealbumin test results as
one of the criteria for selection of a record for screening, only a small number of the
records included prealbumin test results during the same hospitalization as the diarrhea
episode. Therefore, this variable could not be included in the analysis.
Between cases and controls, identical proportions of subjects demonstrated
hypoalbuminemia, while a greater proportion of cases than controls exhibited
lymphocytopenia based on the laboratory’s reference values for each test. However, in
this sample, cases demonstrated significantly higher mean albumin and lymphocyte
values than cases..
Lymphocyte count was not significantly associated with CDAD status in either
univariate or multivariate analysis. Serum albumin was associated on univariate analysis
with CDAD case status, but failed to demonstrate a significant association during
multivariate analysis. The univariate association is consistent with other reported
univariate associations between serum albumin and CDAD (Al-Tureihi et al., 2005,
Andrews et al., 2003, Raveh, Rabinowitz, Breuer, Rudensky, & Yinnon, 2006; Rubin et
al., 1995). Recently, a significant multivariate association was reported between
hypoalbuminemia and CDAD (Peled et al., 2007). In that study, a significant difference
existed between mean albumin scores of cases and controls, and subjects were
categorized for the logistic regression analysis based on a selected cut-point to indicate
hypoalbuminemia. The data group in this present study also exhibited a statistically
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significant difference in mean albumin scores between cases and controls on univariate
testing with a paired t-test. It should be noted that in this sample, identical proportions of
cases and controls had serum albumin levels lower than the laboratory reference low
value of 3.8 mg/100 ml. Only 26% of the entire sample had albumin levels lower than a
value of 3.4 mg/100 ml.
Age
This sample demonstrated a statistically significant difference between the mean
age of cases and controls, but failed to produce an independent association between age
and CDAD status on multivariate analysis. This finding is in contrast to the substantial
support in the research literature for advancing age as a risk factor for CDAD (Bignardi,
1998). The sample in this study was relatively heterogeneous in terms of age, and this
represents a departure from samples in other studies. This broader range of subject ages
may be a reflection of the specific Veteran’s Administration Medical Center population
from which the sample was drawn.
Microenvironmental Exposure Variables
This study included a number of exposures previously identified in the literature
as affecting the bacterial ecology of the intestinal tract. These exposures included
laxative or cathartic drugs, acid suppression drugs, antibiotics, and tube feeding. It was
hypothesized that these variables would not be significant predictors of CDAD status in a
study design that carefully considered criteria for case and control selection and matched
for both temporal and spatial exposure data.
For purposes of this study, an attempt was made to quantify the dose response
phenomenon for microenvironmental exposure through use of standardized measures.
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For drug exposure, the World Health Organization’s Defined Daily Doses were computed
for each class of drug and summed to produce a continuous measure of exposure. For
tube feeding, the measure was the number of days of tube feeding prior to the onset of
diarrhea and stool testing. Although a number of studies have considered these same
variables, exposure has often been measured strictly as a dichotomous variable.
Tube Feeding
This data failed to demonstrate tube feeding exposure as a significant predictor of
CDAD. Although nearly all of the subjects tube fed during the period experienced
enteral nutrition for more than 2 weeks, there were simply not enough subjects in the
sample among either cases or controls who received this therapy. Therefore, there was
not sufficient power to detect a difference between the two groups.
Cathartic Burden
When measured as drug burden based on the total number of Defined Daily Doses
ingested during the exposure period, cathartic drugs failed to demonstrate a significant
exposure risk. Although there was a statistically significant difference between mean
cathartic drug burdens of the two groups, both univariate and multivariate logistic
regression revealed non-significant O.R.’s for this variable.
Acid Suppression Burden
Acid suppression burden considered the DDD’s for both proton pump inhibitor
drugs and histamine 2 blocking agents. Neither category of drug was found to be a
statistically significant predictor of CDAD when measured this way. In this sample
identical or nearly identical portions of both cases and controls had exposure to acid
suppression therapy, so that even if this variable had been measured as binary data,
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similar to some previous studies, it is unlikely that it would have proven to be a predictor.
Although two prospective case-studies have recently reported significant multivariate
associations for acid suppression, both measured exposure based on subject’s reporting of
prescribed drugs prior to hospitalization (Peled et al., 2007; Yearsley et al., 2006) and
thus were subject to recall bias. Likewise, neither study focused on hospital administered
acid suppressive drugs, the most meaningful information available to the bedside
clinician.
Antibiotic Burden
This study demonstrated that an increase in antibiotic drug burden actually
provided a slight decrease in risk of the development of hospital-acquired CDAD. This
finding contrasts sharply with other studies, which measure exposure in other terms such
as the number of drugs, number of prescribed doses, number of days of therapy. In
previous research, a dose-response relationship has been demonstrated for antibiotic
exposure. The decreased dose-response in this study may have occurred for several
reasons. The combined DDD’s of all categories of antibiotics were considered together
as a group, regardless of the therapeutic or chemical classification of the antibiotic, which
may account for some of the differences. Analysis of data by specific drug categories
may have resulted in some demonstration of increased risk. Case-control studies, which
examine specific drugs or drug categories are subject to considerable selection bias,
particularly in prospective studies in which the drug exposure of interest is used as a
criterion for study participation. Drug prescribing patterns vary geographically and
between different health systems, and the antibiotic formulary available to clinicians
varies between institutions, making cross comparisons difficult. It also is possible that
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antibiotic exposure in some studies may actually represent the confounding factor of
severity of illness. The more severely ill individual remains hospitalized longer, thus is
exposed to more drug therapy overall, and more environmental stressors.
Limitations of the Study
A serious limitation of this study was the small sample size obtained for the
number of variables screened. A lack of statistical power may have influenced the failure
to obtain statistical significance for some predictors. Although the original data pool was
very large, the screening criteria and matching criteria were very strict to decrease bias
identified in earlier research. As a result of this screening and matching process, only 66
pairs could be identified from the initial 1, 737 records.
The homogeneity of gender for this sample is also a limitation. The
predominance of male subjects is not representative of the general acute care hospital
population. The data collection process made no attempt to determine ethnicity of the
subjects. Although previous research has not identified any ethnic differences in the
development of CDAD, it is possible that differences in response to exposures,
particularly drug exposures may vary based on genomic differences.
The large number of missing values for the prealbumin variable necessitated
removal of this variable from any type of statistical modeling. Elimination of this
variable, combined with the small number of tube fed subjects, makes it extremely
difficult to determine the impact of nutritional status on development of CDAD among
this sample. Although lymphocyte count provides some information about nutritional
status, serum albumin is influenced by many biologic factors in addition to nutrition and
cannot be considered an accurate measure of nutritional status.
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This study used a retrospective case-control design. Although an attempt was
made to establish a temporal relationship between exposure and disease by excluding
subjects hospitalized less than 2 days or discharged more than 31 days before the onset of
diarrhea symptoms, it is still possible that actual exposure to Clostridium difficile
microorganisms occurred prior to or after hospitalization. The design was also
vulnerable to selection bias, since cases were initially identified via data mining medical
records to identify those with available data points for four specific laboratory tests, one
being the toxin assay for the disease. Therefore, the clinicians caring for the subjects at
the time diarrhea symptoms were identified, introduced a form of diagnostic bias into the
study, which was beyond the control of the researcher. If a clinician believed that CDAD
was a possible differential diagnosis, a specimen was likely submitted. There may have
been additional potentials subjects with diarrhea symptoms who would have tested either
positive or negative for CDAD cytotoxin.
Generalizability
Given the limitations of the sample and the retrospective case-control design,
caution should be used in any attempts to generalize these findings to other acute care
hospital settings. The lack of female subjects and the constricted age range indicate these
findings may not be applicable to other settings. The study site is located in a major
metropolitan area, with numerous other comprehensive hospitals available. Given the
mean age of study participants, Medicare insurance coverage would qualify many of the
subjects for treatment at any of these other institutions. It is impossible to know why an
individual might be hospitalized at a particular institution. Therefore, it is possible that
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other host-related variables exist inherently within the veteran’s population, which were
not measured in this study.
Implications for Nursing Education and Practice
This study presents some important implications for nursing education and
clinical practice. The framework used to organize the study suggests that if clinicians can
identify intrinsic host characteristics that make them more susceptible to disease, the
clinician can alter the external environmental conditions to increase spatial and temporal
distance between the vulnerable individual and the harmful environmental exposure.
This study identified increased length of exposure, increased severity of illness, and a
decrease in antibiotic drug burden as independent predictors of CDAD development
among hospitalized adults. As more virulent strains of Clostridium difficile continue to
emerge, clinicians must develop new strategies for increasing temporal and spatial
distance beyond the currently employed system of universal precautions combined with
isolation of infected persons. Some means of “isolating” will need to occur for the most
severely ill persons.
This is particularly evident in the critical care environment, where most patients
have extensive organ involvement, require multiple means of life support, and have
complex interrelated pathophysiologic derangements. Unfortunately, this is also the
same environment in which traditional spatial distance is limited by design of the unit and
temporal distance is rarely possible due to the high demand for critical care bed
placement in modern hospitals. Therefore, new strategies may be necessary to achieve
spatial distance such as strict stool containment and disposal, limitation of caregivers, and
assignment of infected and non-infected patients to totally different care teams.
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Nurse educators working in both pre-licensure and continuing education settings
face a number of challenges. Through contamination of hands, equipment, and uniforms,
nurses can serve as a vector for transmission of Clostridium difficile spores. Continuing
to teach students and practitioners prevention of infectious disease through traditional
mechanisms of identification and isolation does not fully enable them to appreciate the
importance of identifying the vulnerable, at-risk population to protect them from
exposure. Nurses working in practice settings with clients at high risk for infection, such
as neonatal and bone marrow transplant units, have demonstrated that limitation of
visitation, restriction of access to the care unit, and adherence to use of handwashing and
barrier products can reduce the incidence of infections among high-risk persons.
Educators teaching about infectious disease need to include content about identification
of at-risk clients and increasing spatial and temporal distance between at-risk individuals
and infected individuals.
Nurse administrators may also need to consider changes in work assignment,
visitation policies, and the spatial assignment of individual patients. This will be
problematic given a global nursing shortage. However, nosocomial infections may prove
to be an economic burden that threatens the continued viability of institutions,
particularly in an era when third party payers are choosing to withhold compensation for
problems that develop during an individual patient’s stay within an acute care hospital.
Recommendations for Future Research
Nurses must become increasingly involved in research concerning the epidemiology and
prevention of all types of hospital acquired infections to ensure that predictors and
prevention measures are well grounded and clinically useful.
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Future research regarding CDAD should include measures to determine if other
commonly used measures of disease severity or patient acuity might be as useful in
predicting risk as the Horn Severity of Illness index, particularly tools that are already
widely used by nurses such as the APACHE II scoring system.
More research is needed to understand the relationship between drug exposure
and CDAD. A prospective, multi-center case-control study would enable accumulation
of sufficient data points to determine multivariate associations. There is a definite need
for a standardized measure of drug exposure. Although somewhat tedious, this study
demonstrates that the DDD system is one way in which standardized measures of drug
exposure could be compared across studies.
Two recent publications have identified colonization pressure, the sum of daily
point prevalence rates of disease for each day spent in the environment of exposure, as
significant predictors of CDAD development (Dubberke et al., 2007; Lawrence et al.,
2007). Colonization pressure is a quantifiable way to measure the variable of
environmental stressors identified in the conceptual framework for this study.
Intervention studies to determine strategies for disease prevention could use this concept
as an outcome variable. As a continuous variable, this would offer benefits in study
design and data analysis over traditional binary outcomes.
Conclusions
This study confirmed severity of illness and length of exposure as independent
predictors of the acquisition of hospital-acquired Clostridium difficile-associated
diarrhea. It did not confirm malnutrition as a risk factor as hypothesized. An increase in
the number of Defined Daily Doses of antibiotics was found to indicate a slight decrease
74

in disease risk, a departure from previous research measuring drug exposure in other
ways.
The study supports the use of an ecologic model to help explain the phenomenon
of hospital-acquired CDAD and indicates a framework for future research regarding
intrinsic host characteristics suggesting increased risk, and intervention strategies to
decrease environmental stressors on the vulnerable host.
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Data Collection Worksheet
Exclusion Criteria
NONE of the following located in medical record:
Diagnosis of CDAD within 12 months preceding
hospitalization
History of surgically created chronic diarrhea
History of Crohn’s disease or untreated chronic ulcerative
colitis
History of diarrhea-predominant irritable bowel
syndrome
Diabetic neuropathy with chronic diarrhea
Inclusion Criteria
Case
Diarrhea:

Diarrhea Control
Diarrhea:

>2 stools in 24 hours
loose and unformed or liquid
consistency
concurrent or within 7 days of
positive finding(s) for:

>2 stools in 24 hours
loose and unformed or liquid
consistency
concurrent or within 7 days of
negative finding(s) for:
Stool culture for toxinproducing strain of Cd

Stool culture for toxinproducing strain of Cd
Date:
Cell culture cytotoxin assay

Date:
Cell culture cytotoxin assay

Date:
EIA toxin test

Date:
EIA toxin test

Date:
Endoscopy with
pseudomembranous colitis

Date:
Endoscopy with
pseudomembranous colitis

Date:

Date:

Demographic Data
Age on date of admission:

Gender:
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Male

Female

Matching Information
Date

Unit

Admit
Transfer
Transfer

Date

Unit

Date

Transfer
Transfer
Transfer

Unit

Transfer
Transfer
Discharge

Severity of Illness Index
Characteristic
Stage of Principal
Diagnosis

LEVELS
1
Asymptomati
c

Complications

None or very
minor

Interactions

None or
minor
Low
Noninvasive
Diagnostic or
Minor
Therapeutic
Prompt

Dependency
Procedures (NonO.R.)

Respons
e to
therapy

Rate
Resolutio
n of Acute
Symptoms

Complete

2
Moderate
Manifestation
s
Moderate –
less important
than principal
diagnosis
Moderate

3
Major
Manifestations
Major – as or
more
important than
principal Dx
Major

4
Catastrophic
Manifestation
s
Catastrophic –
death or major
permanent
disability
Catastrophic

Moderate
Therapeutic or
Invasive
Diagnostic

Major
Nonemergenc
y Life Support

Extreme
Emergency
Life Support

Moderate
Delay
Extensive but
incomplete

Serious Delay

No Response

Incomplete
and Disabling

No Resolution

Bowel preparation regimen
No laxatives or bowel preparation documented
Enema
Colostomy irrigation
Cathartic:
____________________________________
Cathartic:
____________________________________
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NO EVIDENCE that prep
being administered for
colonoscopy to diagnose
Pseudomembranous colitis

Tube feeding
No tube feeding documented
Type of tube

Number of days
used

percutaneously inserted tube
enteral

gastric

nasoenteral tube
nasogastric or orogastric tube

Nutritional indices within first 7 days of hospitalization
Laboratory indicator

Lab normal Value

Date

Hospital
Day #

Serum albumin
Pre-albumin
Lymphocyte count
Gastric acid suppression
A

B

C

D

E

F

Drug name

Category

Dosage

DDD

DDD
Units

# Doses

PPI
H2 blocker
PPI
H2 blocker
PPI
H2 blocker
PPI
H2 blocker
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G
(E) x (F)
Burden

Antibiotic exposure
A

B

C

D

E

F

G

Drug name

Category

Dosage

DDD

DDD
Units

# Doses

(E) x (F)
Burden

TOTAL ANTIBIOTIC BURDEN
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Electronic Medical Record Review Protocol

Data Collection Step

Location of Information

1. Verify that potential subject does not meet exclusion
criteria

History and physical

2. Verify that potential subject meets criteria for inclusion
as either case or control

Bowel record

Admitting diagnosis

Laboratory data
Endoscopy data

3. Record age

Patient information

4. Record gender

Patient information

5. Record dates of admission and discharge

Patient information

6. Record dates of transfer within the facility by room
number

Medication Record

7. Complete Severity of Illness Index:
a. Stage of principal diagnosis at admission = peak
extent of organ involvement as manifested by the
patient at admission

History and physical
examination findings

b. Complications = complications of the principal
diagnosis, or complications that are a direct result
of the therapy, hospitalization, or accidents that
arise during hospitalization

Discharge summary

c. Interactions = conditions or problems, other than
the principal diagnosis and complications, that
have no

Discharge summary

d. Physiologic relationship to the principal diagnosis
or that contributed to or caused the illness
represented by the principal diagnosis

History and physical
Discharge summary

e. Dependency = degree to which the patient
Nursing acuity rating
requires more than the minimal level of direct care Nursing care records
for the principal diagnosis. It includes
dependency that is a consequence of the principal
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Data Collection Step

Location of Information

diagnosis, complications, and active interactions.
The rating should be representative of the
patient’s “most of the time” dependency during
the entire hospitalization and the degree to which
“most-of-the-time” level of care is greater than the
minimum expected for that principal diagnosis.
f. Non-operating room procedures = peak
procedural interventions undertaken
EXCLUDING surgical procedures performed in
an operating room. The TYPE of procedure, not
the number of procedures performed, determines
the level of this dimension

Cardiac arrest record

g. Rate of response to therapy = response to the
therapies instituted for the principal diagnosis and
the impact of complications and active
interactions on the hospitalization

Discharge summary

h. Remission of acute symptoms = extent to which a
patient still shows evidence of the acute injury or
illness related to the principal diagnosis,
complications, or active interactions at the time of
discharge, excluding preexisting conditions that
did not change during the hospitalization and for
which no change was expected

Discharge summary

Mechanical ventilation
Laboratory
Diagnostic imaging

8. Determine if bowel preparation was administered during
hospital stay, and if so, record the type of preparation
administered.

Medication
administration record

9. Determine if tube feeding was used during
hospitalization, and if so, record the number of days
administered by the appropriate type of feeding tube

Diet record

10. Record the laboratory value for the first test completed
during the hospitalization. Record the date of specimen
collection. To determine the hospital day number, count
the date of admission as day 1.

Laboratory record

11. Determine gastric acid suppression exposure:
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Data Collection Step

Location of Information

a. Record drug name in column A

Medication Record

b. Check box for correct drug category in column B.
c. Record the drug dosage in Column C

Medication Record

d. Record the Defined Daily Dose (DDD) in Column
D
e. Divide Column C by Column D to determine the
number of DDD units and record value with two
decimal places in Column E

Pocket calculator

f. Record the number of doses received prior to
diagnostic testing for Clostridium difficile in
Column F.

Medication Record

g. Multiply the values in Columns E and F with two
decimal places to determine the drug burden and
record in Column G.

Pocket calculator

h. Add the values of Column G and record the total
Acid Suppressant burden

Pocket calculator

12. Determine the antibiotic exposure
a. Record drug name in column A

Medication Record

b. Check box for correct drug category in column B.

Antibiotic Guide

c. Record the drug dosage in Column C

Medication Record

d. Record the Defined Daily Dose (DDD) in Column Antibiotic Guide
D
e. Divide Column C by Column D to determine the
number of DDD units and record value with two
decimal places in Column E

Pocket calculator

f. Record the number of doses received prior to
diagnostic testing for Clostridium difficile in
Column F. number of doses received during
hospital days 1-30 only.

Medication Record
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Location of Information

g. Multiply the values in Columns E and F with two
decimal places to determine the drug burden and
record in Column G.
h. Add the values of Column G and record the total
Antibiotic burden
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Pocket calculator
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